

CITATION REPORT

List of articles citing

Guidelines for diagnosis of cystic fibrosis in newborns through older adults: Cystic Fibrosis Foundation consensus report

DOI: 10.1016/j.jpeds.2008.05.005
Journal of Pediatrics, 2008, 153, S4-S14.

Source: <https://exaly.com/paper-pdf/43813688/citation-report.pdf>

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
826	By the sweat of our brows: how salty should a person be?. <i>Journal of Pediatrics</i> , 2008 , 153, 735-6	3.6	2
825	Consensus on the use and interpretation of cystic fibrosis mutation analysis in clinical practice. 2008 , 7, 179-96		403
824	Extra corporeal membrane oxygenation (ECMO) therapy in a 3-year-old child with cystic fibrosis: a tale of hope. 2009 , 102 Suppl 1, 54-8		2
823	Clarification of laboratory and clinical variables that influence cystic fibrosis newborn screening with initial analysis of immunoreactive trypsinogen. 2009 , 123, e338-46		41
822	Growth assessment of paediatric patients with CF comparing different auxologic indicators: A multicentre Italian study. 2009 , 49, 335-42		22
821	Emerging roles for CT imaging in cystic fibrosis. 2009 , 252, 327-9		3
820	The very low penetrance of cystic fibrosis for the R117H mutation: a reappraisal for genetic counselling and newborn screening. 2009 , 46, 752-8		87
819	Sweat testing for cystic fibrosis: standards of performance in Australasia. 2009 , 46, 332-7		10
818	The Human Genome: Implications for the Understanding of Human Disease. 2009 , 109-122		
817	Genetics of cystic fibrosis. 2009 , 30, 531-8		29
816	Sweat gland bioelectrics differ in cystic fibrosis: a new concept for potential diagnosis and assessment of CFTR function in cystic fibrosis. 2009 , 64, 932-8		15
815	A new cystic fibrosis newborn screening algorithm: IRT/IRT1 upward arrow/DNA. <i>Journal of Pediatrics</i> , 2009 , 155, 618-22	3.6	27
814	The importance of sweat testing for older siblings of patients with cystic fibrosis identified by newborn screening. <i>Journal of Pediatrics</i> , 2009 , 155, 928-930.e1	3.6	7
813	Cystic Fibrosis Foundation practice guidelines for the management of infants with cystic fibrosis transmembrane conductance regulator-related metabolic syndrome during the first two years of life and beyond. <i>Journal of Pediatrics</i> , 2009 , 155, S106-16	3.6	123
812	Improving the care of infants identified through Cystic Fibrosis newborn screening. <i>Journal of Pediatrics</i> , 2009 , 155, S71-2	3.6	10
811	Inconclusive cystic fibrosis neonatal screening results: long-term psychosocial effects on parents. 2009 , 98, 1927-34		8
810	Cystic fibrosis transmembrane conductance regulator (CFTR) gene mutations and risk for pancreatic adenocarcinoma. 2010 , 116, 203-9		58

809	Borderline sweat test: Utility and limits of genetic analysis for the diagnosis of cystic fibrosis. 2009 , 42, 611-6	11
808	Does the Macroduct collection system reliably define sweat chloride concentration in subjects with intermediate results?. 2009 , 42, 1260-4	10
807	The Role of Mutation and Epimutation in the Development of Human Disease. 2009 , 41-54	1
806	Cystic fibrosis. 2009 , 30, 302-9; quiz 310	12
805	Evaluation of the upper airway in children and adolescents with cystic fibrosis and obstructive sleep apnea syndrome. 2009 , 73, 1780-5	31
804	European best practice guidelines for cystic fibrosis neonatal screening. 2009 , 8, 153-73	155
803	[Protocol for the diagnosis and follow up of patients with cystic fibrosis]. 2009 , 71, 250-64	11
802	[Neonatal screening for cystic fibrosis]. 2009 , 71, 481-2	13
801	Cystic fibrosis. 2009 , 373, 1891-904	972
800	Current world literature. 2009 , 15, 638-44	
799	Hepatobiliary disease in patients with cystic fibrosis. 2009 , 25, 272-8	69
798	Current world literature. 2009 , 25, 285-300	
797	Achieving developmental milestones in a chronically ill patient. 2009 , 34, 11-3	
796	Diagnosing Cystic Fibrosis at All Ages. 2010 , 17, 14-19	
795	Current world literature. 2010 , 16, 623-7	
794	Emerging issues in cystic fibrosis newborn screening. 2010 , 16, 584-90	11
793	Cystic fibrosis-associated liver disease. 2010 , 24, 585-92	67
792	Long-term evaluation of genetic counseling following false-positive newborn screen for cystic fibrosis. 2010 , 19, 199-210	26

791	Cystic fibrosis newborn screening: using experience to optimize the screening algorithm. 2010 , 33, S255-61		15
790	Fatal familial lung disease caused by ABCA3 deficiency without identified ABCA3 mutations. <i>Journal of Pediatrics</i> , 2010 , 157, 62-8	3.6	19
789	The need for quality improvement in sweat testing infants after newborn screening for cystic fibrosis. <i>Journal of Pediatrics</i> , 2010 , 157, 1035-7	3.6	29
788	Can mucoid <i>Pseudomonas aeruginosa</i> be eradicated in children with cystic fibrosis?. 2010 , 45, 566-8		6
787	Measurement of airway ion transport assists the diagnosis of cystic fibrosis. 2010 , 45, 789-95		13
786	An 18-month study of the safety and efficacy of repeated courses of inhaled aztreonam lysine in cystic fibrosis. 2010 , 45, 1121-34		141
785	Non-classic cystic fibrosis associated with D1152H CFTR mutation. 2010 , 77, 355-64		25
784	The Human Genome:. 2010 , 77-87		
783	When the cystic fibrosis label does not fit: a modified uncertainty theory. 2010 , 20, 209-23		37
782	False negative cystic fibrosis newborn screen. 2010 , 49, 214-6		10
781	<i>Exophiala</i> (<i>Wangiella</i>) <i>dermatitidis</i> and cystic fibrosis - Prevalence and risk factors. 2010 , 48 Suppl 1, S4-9		32
780	Molecular Testing for Cystic Fibrosis and CFTR-Related Conditions. 2010 , 149-165		
779	Use of sweat conductivity measurements. 2010 , 47, 390-1		3
778	Lentiviral vectors and cystic fibrosis gene therapy. 2010 , 2, 395-412		18
777	Positive neonatal screening for cystic fibrosis in neonates with renal failure. 2010 , 65, 652-3		2
776	A 21st-century approach to cystic fibrosis: optimizing outcomes across the disease spectrum. 2010 , 51 Suppl 7, S1-7; quiz 3 p following S7		2
775	Diagnosis of adult hereditary pulmonary disease and the role of genetic testing. 2010 , 137, 976-82		4
774	Classic respiratory disease but atypical diagnostic testing distinguishes adult presentation of cystic fibrosis. 2010 , 137, 1157-63		26

773	Effects of gender and age at diagnosis on disease progression in long-term survivors of cystic fibrosis. 2010 , 182, 614-26	89
772	Clinical phenotype and genotype of children with borderline sweat test and abnormal nasal epithelial chloride transport. 2010 , 182, 929-36	44
771	Cystic fibrosis transmembrane conductance regulator channel dysfunction in non-cystic fibrosis bronchiectasis. 2010 , 181, 1078-84	63
770	Multicenter evaluation of infant lung function tests as cystic fibrosis clinical trial endpoints. 2010 , 182, 1387-97	84
769	Approaches to transition in other chronic illnesses and conditions. 2010 , 57, 983-96	23
768	Evaluation of infants and children with refractory lower respiratory tract symptoms. 2010 , 104, 279-83; quiz 283-5, 298	8
767	Bronchiectasis: a continuum of ion transport dysfunction or multiple hits?. 2010 , 181, 1017-9	18
766	Prevalence of dyslipidemia in adults with cystic fibrosis. 2010 , 9, 24-8	55
765	Measuring and improving respiratory outcomes in cystic fibrosis lung disease: opportunities and challenges to therapy. 2010 , 9, 1-16	80
764	Benchmarks for cystic fibrosis carrier screening: a European consensus document. 2010 , 9, 165-78	63
763	[R74W;R1070W;D1270N]: a new complex allele responsible for cystic fibrosis. 2010 , 9, 447-9	6
762	Mutations that permit residual CFTR function delay acquisition of multiple respiratory pathogens in CF patients. 2010 , 11, 140	55
761	CFTR Modulators for the Treatment of Cystic Fibrosis. 2010 , 157-173	7
760	Association of cystic fibrosis genetic modifiers with congenital bilateral absence of the vas deferens. 2010 , 94, 2122-7	17
759	[French guidelines for sweat test practice and interpretation for cystic fibrosis neonatal screening]. 2010 , 17, 1349-58	18
758	Effect of VX-770 in persons with cystic fibrosis and the G551D-CFTR mutation. 2010 , 363, 1991-2003	598
757	Infectiologie respiratoire et mucoviscidose de l'adulte. 2010 , 2, 85-96	
756	A new complex allele of the CFTR gene partially explains the variable phenotype of the L997F mutation. 2010 , 12, 548-55	33

755	Challenges and advances in the development of inhalable drug formulations for cystic fibrosis lung disease. 2011 , 8, 451-66	23
754	Cystic fibrosis and sinusitis in children: outcomes and socioeconomic status. 2011 , 145, 146-53	24
753	Managing cystic fibrosis: strategies that increase life expectancy and improve quality of life. 2011 , 183, 1463-71	207
752	Changing epidemiology and clinical issues arising in an ageing cystic fibrosis population. 2011 , 5, 105-19	50
751	Type of CFTR mutation determines risk of pancreatitis in patients with cystic fibrosis. 2011 , 140, 153-61	176
750	Mast cell-associated alveolar inflammation in patients with atopic uncontrolled asthma. 2011 , 127, 905-12.e1-773	
749	Cystic fibrosis in Chilean patients: Analysis of 36 common CFTR gene mutations. 2011 , 10, 66-70	9
748	Optimal DNA tier for the IRT/DNA algorithm determined by CFTR mutation results over 14 years of newborn screening. 2011 , 10, 278-81	30
747	Ambulatory quantitative waking and sleeping cough assessment in patients with cystic fibrosis. 2011 , 10, 193-200	13
746	Assessment of CFTR function in homozygous R117H-7T subjects. 2011 , 10, 326-32	24
745	A recurrent deep-intronic splicing CF mutation emphasizes the importance of mRNA studies in clinical practice. 2011 , 10, 479-82	18
744	Clinical practices for intermediate sweat tests following abnormal cystic fibrosis newborn screens. 2011 , 10, 460-5	9
743	Evaluation of the disease liability of CFTR variants. 2011 , 742, 355-72	21
742	Infectiologie respiratoire et mucoviscidose. 2011 , 3, 72-83	
741	Differential global gene expression in cystic fibrosis nasal and bronchial epithelium. 2011 , 98, 327-36	48
740	Therapeutics development for cystic fibrosis: a successful model for a multisystem genetic disease. 2011 , 62, 107-25	44
739	New clinical diagnostic procedures for cystic fibrosis in Europe. 2011 , 10 Suppl 2, S53-66	74
738	Recommendations for the classification of diseases as CFTR-related disorders. 2011 , 10 Suppl 2, S86-102	250

737	Cystic fibrosis and anaesthesia. 2011 , 11, 204-209	70
736	A case Report of a Classic Cystic fibrosis Pediatric Patient in Korea Carrying Very Rare CFTR Gene Mutations (D993Y and Q220X). 2011 , 21, 61	2
735	A pre-post retrospective study of patients with cystic fibrosis and gastrostomy tubes. 2011 , 53, 453-8	20
734	Genotype-phenotype correlation in cystic fibrosis patients bearing [H939R;H949L] allele. 2011 , 34, 416-20	8
733	Is cystic fibrosis genetic medicine's canary?. 2011 , 54, 316-31	8
732	Arquitetura do sono e perfil respiratório polissonográfico de crianças e adolescentes com fibrose cística. 2011 , 87, 63-69	10
731	Shwachman-Kulczycki score still useful to monitor cystic fibrosis severity. 2011 , 66, 979-83	19
730	The etiology of acute recurrent pancreatitis in children: a challenge for pediatricians. 2011 , 40, 517-21	56
729	Cystic fibrosis testing 8 years on: lessons learned from carrier screening and sequencing analysis. 2011 , 13, 166-72	47
728	Patient and family issues regarding genetic testing for cystic fibrosis: a review of prenatal carrier testing and newborn screening. 2011 , 29, 303-29	2
727	Cystic Fibrosis. 2011 , 191-198	
726	Vitamin E supplementation in people with cystic fibrosis. 2011 ,	6
725	Motor delay in cystic fibrosis infants: an observational study. 2011 , 87, 769-73	5
724	A tailored approach to family-centered genetic counseling for cystic fibrosis newborn screening: the Wisconsin model. 2011 , 20, 115-28	19
723	Staff costs of hospital-based outpatient care of patients with cystic fibrosis. 2011 , 1, 10	1
722	Activated MCTC mast cells infiltrate diseased lung areas in cystic fibrosis and idiopathic pulmonary fibrosis. 2011 , 12, 139	55
721	Predictors of insufficient sweat production during confirmatory testing for cystic fibrosis. 2011 , 46, 23-30	19
720	Inhaled hypertonic saline in infants and toddlers with cystic fibrosis: short-term tolerability, adherence, and safety. 2011 , 46, 666-71	24

719	A novel lung disease phenotype adjusted for mortality attrition for cystic fibrosis genetic modifier studies. 2011 , 46, 857-69	36
718	Clinical outcomes in infants with cystic fibrosis transmembrane conductance regulator (CFTR) related metabolic syndrome. 2011 , 46, 1079-84	36
717	Factors accounting for a missed diagnosis of cystic fibrosis after newborn screening. 2011 , 46, 1166-74	23
716	The dangers of including nonclassical cystic fibrosis variants in population-based screening panels: p.L997F, further genotype/phenotype correlation data. 2011 , 13, 1042-4	16
715	The need for vigilance: the case of a false-negative newborn screen for cystic fibrosis. 2011 , 128, e446-9	8
714	Psychosocial consequences of false-positive newborn screens for cystic fibrosis. 2011 , 21, 174-86	55
713	Cystic fibrosis newborn screening: distribution of blood immunoreactive trypsinogen concentrations in hypertrypsinemic neonates. 2012 , 4, 17-23	14
712	CFTR transcription defects in pancreatic sufficient cystic fibrosis patients with only one mutation in the coding region of CFTR. 2011 , 48, 235-41	10
711	Kids in America: Newborn Screening for Cystic Fibrosis. 2011 , 42, 595-601	3
710	The D1152H cystic fibrosis mutation in prenatal carrier screening, patients and prenatal diagnosis. 2011 , 18, 169-72	9
709	Parental understanding of newborn screening for cystic fibrosis after a negative sweat-test. 2011 , 127, 276-83	22
708	The Novel CFTR Mutation A457P in a Male with a Delayed Diagnosis of Cystic Fibrosis. 2011 , 2011, 903910	1
707	Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809. 2011 , 108, 18843-8	773
706	A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. 2011 , 365, 1663-72	1465
705	Avances en fibrosis quística. 2011 , 22, 150-159	1
704	A homozygous missense mutation in SCNN1A is responsible for a transient neonatal form of pseudohypoaldosteronism type 1. 2011 , 301, E467-73	30
703	Newborn screening for cystic fibrosis. 2012 , 24, 329-35	51
702	Nutrition Management of the Infant Identified With Cystic Fibrosis. 2012 , 27, 260-269	1

701	CLSI Announces Guidelines for Newborn Screening for Cystic Fibrosis. 2012 , 43, 31-32	
700	To sweat or not to sweat: is that enough to diagnose cystic fibrosis?. 2012 , 186, 700-1	2
699	Adrenergic sweat secretion as a diagnostic test for cystic fibrosis. 2012 , 186, 732-9	64
698	Diagnosis of Cystic Fibrosis in Adults. 2012 , 19, 159-164	2
697	High prevalence of azole-resistant <i>Aspergillus fumigatus</i> in adults with cystic fibrosis exposed to itraconazole. 2012 , 56, 869-74	139
696	Early in vivo testing to assess new therapeutic interventions in CF patients. 2012 , 18, 663-73	0
695	Mucoviscidose et conseil génétique. 2012 , 9, 1-7	
694	Anti-IgE therapy for allergic bronchopulmonary aspergillosis in people with cystic fibrosis. 2012 ,	
693	Totally implantable central venous access ports in patients with cystic fibrosis: a multicenter prospective cohort study. 2012 , 13, 290-5	14
692	Measurements of CFTR-mediated Cl ⁻ secretion in human rectal biopsies constitute a robust biomarker for Cystic Fibrosis diagnosis and prognosis. 2012 , 7, e47708	42
691	Role of cystic fibrosis transmembrane conductance regulator in patients with chronic sinopulmonary disease. 2012 , 142, 996-1004	15
690	Genetics and Pathophysiology of Cystic Fibrosis. 2012 , 753-762	2
689	Diagnosis and Presentation of Cystic Fibrosis. 2012 , 763-769	3
688	Pulmonary Complications of Liver Disease. 2012 , 255-266	
687	Nutrition for pregnant women who have cystic fibrosis. 2012 , 112, 1943-8	9
686	A survey on pulmonary pathogens and their antibiotic susceptibility among cystic fibrosis patients. 2012 , 16, 122-128	3
685	Noninvasive Measurement of Carboxyhemoglobin in Cystic Fibrosis Patients by Pulse CO-Oximeter. 2012 , 25, 101-103	1
684	Assessing the Disease-Liability of Mutations in CFTR. 2012 , 2, a009480	54

683	Assessment of Aspergillus sensitization or persistent carriage as a factor in lung function impairment in cystic fibrosis patients. 2012 , 44, 842-7	53
682	Cystic Fibrosis. 2012 , 568-579	0
681	CFTR: folding, misfolding and correcting the E508 conformational defect. 2012 , 18, 81-91	264
680	Chronic Stenotrophomonas maltophilia infection and exacerbation outcomes in cystic fibrosis. 2012 , 11, 8-13	58
679	Ancestral haplotype 8.1 and lung disease severity in European cystic fibrosis patients. 2012 , 11, 63-7	19
678	Comparing age of cystic fibrosis diagnosis and treatment initiation after newborn screening with two common strategies. 2012 , 11, 150-3	17
677	Six minute walk test Z score: correlations with cystic fibrosis severity markers. 2012 , 11, 253-6	9
676	Feasibility of using pedometers to measure daily step counts in cystic fibrosis and an assessment of its responsiveness to changes in health state. 2012 , 11, 216-22	15
675	A review of pathophysiology and management of fetuses and neonates with meconium ileus for the pediatric surgeon. 2012 , 47, 772-81	89
674	Evaluating genomic tests from bench to bedside: a practical framework. 2012 , 12, 117	11
673	State of progress in treating cystic fibrosis respiratory disease. 2012 , 10, 88	46
672	Clinical evidence that V456A is a Cystic Fibrosis causing mutation in South Asians. 2012 , 11, 312-5	5
671	Risk factors for age at initial Pseudomonas acquisition in the cystic fibrosis epic observational cohort. 2012 , 11, 446-53	61
670	Cystic fibrosis transmembrane conductance regulator (CFTR) gene mutations in pancreatitis. 2012 , 11, 355-62	71
669	Zijn we tevreden met E diagnose?. 2012 , 80, 66-70	1
668	Detection of a large heterozygous deletion and a splicing defect in the CFTR transcripts from nasal swab of a Japanese case of cystic fibrosis. 2012 , 57, 427-33	11
667	Functional Aspects of an Organic Respiratory Disorder: Cystic Fibrosis. 2012 , 19-47	2
666	Lessons learned from 20 years of newborn screening for cystic fibrosis. 2012 , 196, 67-70	42

665	Alpha-1 antitrypsin deficiency and other metabolic liver diseases. 2012 , 245-258	
664	Poly Thymidine Polymorphism and Cystic Fibrosis in a Non-Caucasian Population. 2012 , 32, 241-246	10
663	Cystic fibrosis transmembrane conductance regulator gene abnormalities in patients with asthma and recurrent neutrophilic bronchitis. 2012 , 19, 46-8	8
662	Cystic Fibrosis. 2012 , 544-548	2
661	[Cystic fibrosis in adults: experience of a national reference center]. 2012 , 140, 841-6	
660	Pancreatitis in Cystic Fibrosis and CFTR-Related Disorder. 2012 ,	0
659	Conclusion. 2012 ,	
658	A survey on pulmonary pathogens and their antibiotic susceptibility among cystic fibrosis patients. 2012 , 16, 122-128	1
657	Anthropometric and dietary intake indicators as predictors of pulmonary function in cystic fibrosis patients. 2012 , 38, 470-6	6
656	Elevated sweat chloride concentration in children without cystic fibrosis who are receiving topiramate therapy. 2012 , 47, 429-33	10
655	Cystic fibrosis: an unusual neonatal presentation. 2012 , 47, 620-2	2
654	Lung function distinguishes preschool children with CF from healthy controls in a multi-center setting. 2012 , 47, 597-605	32
653	Analysis of the associations between lung function and clinical features in preschool children with cystic fibrosis. 2012 , 47, 574-81	28
652	Comparison of quantitative sweat chloride methods after positive newborn screen for cystic fibrosis. 2012 , 47, 736-42	13
651	Urinary desmosine: a biomarker of structural lung injury during CF pulmonary exacerbation. 2012 , 47, 856-63	17
650	Clearance of initial mucoid <i>Pseudomonas aeruginosa</i> in patients with cystic fibrosis. 2012 , 47, 1113-22	8
649	Prospective and parallel assessments of cystic fibrosis newborn screening protocols in the Czech Republic: IRT/DNA/IRT versus IRT/PAP and IRT/PAP/DNA. 2012 , 171, 1223-9	22
648	Elevated gamma-glutamyltransferase is associated with mortality in lung transplantation for cystic fibrosis. 2012 , 25, 78-86	6

647	Mycobactĕries non tuberculeuses et mucoviscidose. 2012 , 14, 35-41		
646	Heritability of respiratory infection with <i>Pseudomonas aeruginosa</i> in cystic fibrosis. <i>Journal of Pediatrics</i> , 2012 , 161, 290-5.e1	3.6	24
645	Pulmonary complications of genetic disorders. 2012 , 13, 2-9		5
644	Evidence for decline in the incidence of cystic fibrosis: a 35-year observational study in Brittany, France. 2012 , 7, 14		43
643	Exhaled breath condensate purines correlate with lung function in infants and preschoolers. 2013 , 48, 182-7		18
642	Evaluation of the intestinal current measurement method as a diagnostic test for cystic fibrosis. 2013 , 48, 229-35		23
641	Neonatal cholestasis with ductal paucity and steatosis. 2013 , 50, 316-20		2
640	Apoptotic process in cystic fibrosis cells. 2013 , 18, 1029-38		20
639	Rectal forceps biopsy procedure in cystic fibrosis: technical aspects and patients perspective for clinical trials feasibility. 2013 , 13, 91		22
638	Defining the disease liability of variants in the cystic fibrosis transmembrane conductance regulator gene. 2013 , 45, 1160-7		413
637	Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation. 2013 , 187, 1219-25		354
636	Cystic Fibrosis. 2013 , 1-54		2
635	Novel CFTR variants identified during the first 3 years of cystic fibrosis newborn screening in California. 2013 , 15, 710-22		23
634	Test del sudor. 2013 , 11, 291-294		
633	Cystic Fibrosis. 2013 , 268-270		1
632	The Reconfiguration of the Relationship to Care for a Rare Disease: Neonatal Expended Screening in a Socio-material Perspective. 2013 , 18, 115-138		
631	Prognostic value of six minute walk test in cystic fibrosis adults. 2013 , 107, 1881-7		37
630	[Mucoviscidosis: CFTR mutation-specific therapy: a ray of sunshine in a cloudy sky]. 2013 , 20, 63-73		2

629	CFTR2: How will it help care?. 2013 , 14 Suppl 1, 2-5		41
628	Impaired CFTR function in mild cystic fibrosis associated with the S977F/T5TG12 complex allele in trans with F508del mutation. 2013 , 12, 821-5		4
627	Newborn screening for cystic fibrosis in Switzerland--consequences after analysis of a 4 months pilot study. 2013 , 12, 667-74		7
626	Anti-IgE therapy for allergic bronchopulmonary aspergillosis in people with cystic fibrosis. 2013 , CD010288		8
625	Non-cystic fibrosis bronchiectasis. 2013 , 188, 647-56		251
624	La croissance des filles suivies pour mucoviscidose de 8 à 20 ans : les données du registre français. 2013 , 20, H81-H83		
623	Effects of immediate telephone follow-up with providers on sweat chloride test timing after cystic fibrosis newborn screening identifies a single mutation. <i>Journal of Pediatrics</i> , 2013 , 162, 522-9	3.6	5
622	Contemporary topics in pediatric pulmonology for the primary care clinician. 2013 , 43, 130-56		1
621	Ataluren as an agent for therapeutic nonsense suppression. 2013 , 64, 407-25		134
620	Change in sweat chloride as a clinical end point in cystic fibrosis clinical trials: the ivacaftor experience. 2013 , 143, 14-18		73
619	Cystic fibrosis testing in a referral laboratory: results and lessons from a six-year period. 2013 , 3, 3		2
618	High rhinovirus burden in lower airways of children with cystic fibrosis. 2013 , 143, 782-790		61
617	Electrochemical detection of chloride levels in sweat using silver nanoparticles: a basis for the preliminary screening for cystic fibrosis. 2013 , 138, 4292-7		68
616	Misdiagnosis of cystic fibrosis: experience from Germany. 2013 , 12, 68-73		9
615	Exhaled molecular profiles in the assessment of cystic fibrosis and primary ciliary dyskinesia. 2013 , 12, 454-60		40
614	Epidemiology of nontuberculous mycobacterial infections and associated chronic macrolide use among persons with cystic fibrosis. 2013 , 188, 807-12		101
613	Gastrostomy in children with cystic fibrosis and portal hypertension. 2013 , 57, 245-7		13
612	Lung clearance index and high-resolution computed tomography scores in primary ciliary dyskinesia. 2013 , 188, 545-9		61

611	Relationship between body balance, lung function, nutritional status and functional capacity in adults with cystic fibrosis. 2013 , 17, 450-7	7
610	Nutrition and Cystic Fibrosis. 2013 , 787-808	
609	Cystic Fibrosis Presenting in Adulthood. 2013 , 20, 1-5	
608	Screening for cystic fibrosis: what every NP should know. 2013 , 38, 24-32; quiz 32-3	
607	Association of lung function, chest radiographs and clinical features in infants with cystic fibrosis. 2013 , 42, 1545-52	20
606	Small airway involvement in cystic fibrosis lung disease: routine spirometry as an early and sensitive marker. 2013 , 48, 1081-8	25
605	Newborn screening policy and practice issues for nurses. 2013 , 42, 718-29	6
604	Understanding the relationship between sweat chloride and lung function in cystic fibrosis. 2013 , 144, 1418	7
603	High serum retinol and lung function in young patients with cystic fibrosis. 2013 , 56, 657-62	8
602	Response. 2013 , 144, 1418-1419	1
601	Benefits of neuromuscular electrical stimulation prior to endurance training in patients with cystic fibrosis and severe pulmonary dysfunction. 2013 , 143, 485-493	28
600	Development, clinical utility, and place of ivacaftor in the treatment of cystic fibrosis. 2013 , 7, 929-37	11
599	A first-year dornase alfa treatment impact on clinical parameters of patients with cystic fibrosis: the Brazilian cystic fibrosis multicenter study. 2013 , 31, 420-30	2
598	Relevance of Nasal Potential Difference in Diagnosis of Cystic Fibrosis Among Children. 2013 , 49, 29	
597	Cystic fibrosis. 2013 , 43, 144-50	5
596	Diagnostic contribution of molecular analysis of the cystic fibrosis transmembrane conductance regulator gene in patients suspected of having mild or atypical cystic fibrosis. 2013 , 39, 181-9	5
595	Effect that an educational program for cystic fibrosis patients and caregivers has on the contamination of home nebulizers. 2014 , 40, 119-27	12
594	Ivacaftor Therapy in CF Patients: Single Center Experience. 2014 , 2014, 947923	

593	An infant with poor weight gain and hypochloremic metabolic alkalosis: a case report. 2014 , 7, 389-91	4
592	Novel Mutation in the CFTR Gene of Cystic Fibrosis Patients in Oman. 2014 , 05,	1
591	Quality improvement initiative to reduce deep vein thrombosis associated with peripherally inserted central catheters in adults with cystic fibrosis. 2014 , 11, 1404-10	15
590	Twenty-five-year outbreak of <i>Pseudomonas aeruginosa</i> infecting individuals with cystic fibrosis: identification of the prairie epidemic strain. 2014 , 52, 1127-35	38
589	Pulsed direct and constant direct currents in the pilocarpine iontophoresis sweat chloride test. 2014 , 14, 198	6
588	Assessment of IgG antibodies to <i>Pseudomonas aeruginosa</i> in patients with cystic fibrosis by an enzyme-linked immunosorbent assay (ELISA). 2014 , 9, 158	15
587	The CF-modifying gene EHF promotes p.Phe508del-CFTR residual function by altering protein glycosylation and trafficking in epithelial cells. 2014 , 22, 660-6	19
586	Lack of harmonization in sweat testing for cystic fibrosis - a national survey. 2014 , 74, 708-12	8
585	Cystic Fibrosis. 2014 ,	
584	Cystic fibrosis related liver disease--another black box in hepatology. 2014 , 15, 13529-49	37
583	A salty cause of cough in a 24-year-old man. 2014 , 2014, 71-3	
582	Testing two different doses of tiotropium Respimat [®] in cystic fibrosis: phase 2 randomized trial results. 2014 , 9, e106195	10
581	Longevity of patients with cystic fibrosis in 2000 to 2010 and beyond: survival analysis of the Cystic Fibrosis Foundation patient registry. 2014 , 161, 233-41	221
580	Implementation of a quality improvement program to improve sweat test performance in a pediatric hospital. 2014 , 138, 920-2	6
579	Vitamin E supplementation in people with cystic fibrosis. 2014 , CD009422	7
578	Does integration of various ion channel measurements improve diagnostic performance in cystic fibrosis?. 2014 , 11, 562-70	8
577	Fifteen-year-old girl with severe obstructive lung disease, pansinusitis, and failure to thrive. 2014 , 53, 1016-8	
576	Uncertain diagnosis after newborn screening for cystic fibrosis: An ethics-based approach to a clinical dilemma. 2014 , 49, 1-7	15

575	HLA frequencies and associations in cystic fibrosis. 2014 , 83, 27-31	
574	Tracheomalacia is associated with lower FEV1 and Pseudomonas acquisition in children with CF. 2014 , 49, 960-70	34
573	Diagnosis of cystic fibrosis in the kindred of an infant with CFTR-related metabolic syndrome: importance of follow-up that includes monitoring sweat chloride concentrations over time. 2014 , 49, E103-8	5
572	Case History: Kalydeco [®] (VX-770, Ivacaftor), a CFTR Potentiator for the Treatment of Patients with Cystic Fibrosis and the G551D-CFTR Mutation. 2014 , 49, 383-398	6
571	Intestinal current measurement versus nasal potential difference measurements for diagnosis of cystic fibrosis: a case-control study. 2014 , 14, 156	11
570	Challenging the diagnosis of cystic fibrosis in a patient carrying the 186-8T/C allelic variant in the CF transmembrane conductance regulator gene. 2014 , 14, 44	0
569	False-negative sweat chloride testing in a child with cystic fibrosis and undiagnosed hypohidrotic ectodermal dysplasia. 2014 , 53, 1203-5	1
568	Aspergillus sensitization or carriage in cystic fibrosis patients. 2014 , 33, 680-6	22
567	Does extensive genotyping and nasal potential difference testing clarify the diagnosis of cystic fibrosis among patients with single-organ manifestations of cystic fibrosis?. 2014 , 69, 254-60	36
566	Sweat chloride as a biomarker of CFTR activity: proof of concept and ivacaftor clinical trial data. 2014 , 13, 139-47	95
565	Cribado neonatal de fibrosis quística. 2014 , 12, 34-38	
564	Genetics of cystic fibrosis: CFTR mutation classifications toward genotype-based CF therapies. 2014 , 52, 94-102	68
563	Prediction of acute pancreatitis risk based on PIP score in children with cystic fibrosis. 2014 , 13, 579-84	16
562	Lung disease modifier genes in cystic fibrosis. 2014 , 52, 83-93	54
561	Active video games as an exercise tool for children with cystic fibrosis. 2014 , 13, 341-6	24
560	Cystic fibrosis: NHLBI Workshop on the Primary Prevention of Chronic Lung Diseases. 2014 , 11 Suppl 3, S161-8	28
559	Sweat conductivity: an accurate diagnostic test for cystic fibrosis?. 2014 , 13, 528-33	28
558	Nasal potential difference measurements in diagnosis of cystic fibrosis: an international survey. 2014 , 13, 24-8	31

557	Sixty-five years since the New York heat wave: advances in sweat testing for cystic fibrosis. 2014 , 49, 106-17	48
556	Genetic, cell biological, and clinical interrogation of the CFTR mutation c.3700 A>G (p.Ile1234Val) informs strategies for future medical intervention. 2014 , 16, 625-32	29
555	Exon identity crisis: disease-causing mutations that disrupt the splicing code. 2014 , 15, 201	82
554	Eradication of <i>Pseudomonas aeruginosa</i> in adults with cystic fibrosis. 2014 , 1, e000021	17
553	Pediatric rhinosinusitis. 2014 , 47, 733-46	30
552	Electrophysiological evaluation of cystic fibrosis conductance transmembrane regulator (CFTR) expression in human monocytes. 2014 , 1840, 3088-95	8
551	Evaluation of micronutrient profile of North Indian children with cystic fibrosis: a case-control study. 2014 , 75, 762-6	12
550	Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) prevents apoptosis induced by hydrogen peroxide in basilar artery smooth muscle cells. 2014 , 19, 1317-29	17
549	Molecular testing for cystic fibrosis carrier status practice guidelines: recommendations of the National Society of Genetic Counselors. 2014 , 23, 5-15	23
548	Clinical investigational studies for validation of a next-generation sequencing in vitro diagnostic device for cystic fibrosis testing. 2014 , 14, 605-22	23
547	Cystic fibrosis: An update for clinicians. Part 1: Nutrition and gastrointestinal complications. 2014 , 29, 1344-55	17
546	Serology as a diagnostic tool for predicting initial <i>Pseudomonas aeruginosa</i> acquisition in children with cystic fibrosis. 2014 , 13, 542-9	12
545	Relationship between sweat chloride, sodium, and age in clinically obtained samples. 2014 , 13, 10-4	19
544	Advances in the diagnosis and treatment of cystic fibrosis. 2014 , 61, 225-43	10
543	Is there evidence for correct diagnosis in cystic fibrosis registries?. 2014 , 13, 275-80	13
542	A new method of sweat testing: the CF Quantum [®] sweat test. 2014 , 13, 520-7	24
541	Cystic fibrosis. 2014 , 35, 194-205	26
540	CFTR functional measurements in human models for diagnosis, prognosis and personalized therapy: Report on the pre-conference meeting to the 11th ECFS Basic Science Conference, Malta, 26-29 March 2014. 2014 , 13, 363-72	28

539	European Cystic Fibrosis Society Standards of Care: Best Practice guidelines. 2014 , 13 Suppl 1, S23-42	328
538	Detection of Anomalous Sodium Chloride Concentrations in Perspiration Using Microsensors. 2014 ,	
537	Genomic breakthroughs in the diagnosis and treatment of cystic fibrosis. 2014 , 114, 36-43; quiz 44-5	4
536	Improving the Rate of Sufficient Sweat Collected in Infants Referred for Sweat Testing in Michigan. 2014 , 1, 2333794X14553625	1
535	Cardiorespiratory and sensory responses to exercise in adults with mild cystic fibrosis. 2015 , 119, 1289-96	11
534	Intestinal inflammation and impact on growth in children with cystic fibrosis. 2015 , 60, 521-6	64
533	Precision Genomic Medicine in Cystic Fibrosis. 2015 , 8, 606-10	19
532	Symposium Summaries. 2015 , 50 Suppl 41, S108-92	1
531	Within-host microevolution of <i>Pseudomonas aeruginosa</i> in Italian cystic fibrosis patients. 2015 , 15, 218	39
530	<i>Burkholderia cepacia</i> complex: clinical course in cystic fibrosis patients. 2015 , 15, 158	22
529	Impaired cardiac and peripheral hemodynamic responses to inhaled β_2 agonist in cystic fibrosis. 2015 , 16, 103	11
528	The Sino-Nasal Outcome Test-22 as a tool to identify chronic rhinosinusitis in adults with cystic fibrosis. 2015 , 5, 1111-7	12
527	Risk factors for lung function decline in a large cohort of young cystic fibrosis patients. 2015 , 50, 763-70	71
526	Utility of a very high IRT/No mutation referral category in cystic fibrosis newborn screening. 2015 , 50, 771-80	14
525	Country to country variation: what can be learnt from national cystic fibrosis registries. 2015 , 21, 585-90	8
524	Medical reversal of chronic sinusitis in a cystic fibrosis patient with ivacaftor. 2015 , 5, 178-81	28
523	Is the type of chronic pulmonary infection a determinant of lung function outcomes in adult patients with cystic fibrosis?. 2012 , 77, 122-8	5
522	Ultrasound echo-intensity predicts severe pancreatic affection in cystic fibrosis patients. 2015 , 10, e0121121	5

521	Changes in cystic fibrosis airway microbial community associated with a severe decline in lung function. 2015 , 10, e0124348		49
520	Profile of lumacaftor/ivacaftor combination: potential in the treatment of cystic fibrosis. 2015 , 61		
519	A Genotypic-Oriented View of CFTR Genetics Highlights Specific Mutational Patterns Underlying Clinical Macrocategories of Cystic Fibrosis. 2015 , 21, 257-75		23
518	ESPGHAN and NASPGHAN Report on the Assessment of Exocrine Pancreatic Function and Pancreatitis in Children. 2015 , 61, 144-53		32
517	Reduced risk of nontuberculous mycobacteria in cystic fibrosis adults receiving long-term azithromycin. 2015 , 14, 594-9		28
516	Demographic, clinical, and laboratory parameters of cystic fibrosis during the last two decades: a comparative analysis. 2015 , 15, 3		12
515	New challenges in the diagnosis and management of cystic fibrosis. <i>Journal of Pediatrics</i> , 2015 , 166, 1337-41		32
514	Long-term outcomes of children with intermediate sweat chloride values in infancy. <i>Journal of Pediatrics</i> , 2015 , 166, 1469-74.e1-3	3.6	35
513	[Lung diseases in children]. 2015 , 55, 545-53		2
512	Assessment of Parental Understanding of Positive Newborn Screening Results and Carrier Status for Cystic Fibrosis with the use of a Short Educational Video. 2015 , 24, 473-81		11
511	Biomarkers in Paediatric Cystic Fibrosis Lung Disease. 2015 , 16, 213-8		17
510	Anti-IgE therapy for allergic bronchopulmonary aspergillosis in people with cystic fibrosis. 2015 , CD010288		10
509	Association between Chronic Rhinosinusitis and Health-Related Quality of Life in Adults with Cystic Fibrosis. 2015 , 12, 1163-9		9
508	Stratifying Cystic Fibrosis Risk for Newborn Screen Infants With Equivocal Sweat Chloride Levels. 2015 , 136, e1490		3
507	Challenges in Cystic Fibrosis Newborn Screening and Recommendations for Primary Care Physicians. 2015 , 136, 1181-4		3
506	Diagnostic Accuracy of a Short Endoscopic Secretin Test in Patients With Cystic Fibrosis. 2015 , 44, 1266-72		17
505	False-Positive and False-Negative Sweat Tests: Systematic Review of the Evidence. 2015 , 28, 198-211		6
504	The Evolution of Cystic Fibrosis Care. 2015 , 148, 533-542		32

503	Nasal potential difference: Best or average result for CFTR function as diagnostic criteria for cystic fibrosis?. 2015 , 14, 310-6	8
502	Association of sweat chloride concentration at time of diagnosis and CFTR genotype with mortality and cystic fibrosis phenotype. 2015 , 14, 580-6	25
501	Diagnostic accuracy of secretin-stimulated ultrasonography of the pancreas assessing exocrine pancreatic failure in cystic fibrosis and chronic pancreatitis. 2015 , 50, 601-10	8
500	Exercise intolerance, malnutrition, abnormal sweat chloride levels, and two CFTR mutations: is it cystic fibrosis?. 2015 , 29, 201-4	1
499	Novel outcome measures for clinical trials in cystic fibrosis. 2015 , 50, 302-315	29
498	Characterization of gene mutations and phenotypes of cystic fibrosis in Chinese patients. 2015 , 20, 312-8	24
497	Forced oscillations and respiratory system modeling in adults with cystic fibrosis. 2015 , 14, 11	17
496	Gene Therapy in Cystic Fibrosis. 2015 , 247-260	2
495	Early manifestations of cystic fibrosis in a premature patient with complex meconium ileus at birth. 2015 , 33, 241-245	
494	[Early manifestations of cystic fibrosis in a premature patient with complex meconium ileus at birth]. 2015 , 33, 241-5	2
493	Nutrition Management of Cystic Fibrosis in the 21st Century. 2015 , 30, 488-500	21
492	Benign outcome among positive cystic fibrosis newborn screen children with non-CF-causing variants. 2015 , 14, 714-9	22
491	Functional Evaluation of Cystic Fibrosis Transmembrane Conductance Regulator. 2015 , 73-91	
490	Changes in Mineral Micronutrient Status During and After Pulmonary Exacerbation in Adults With Cystic Fibrosis. 2015 , 30, 838-43	7
489	Fibrosis quística: detección bioquímica y diagnóstico molecular. 2015 , 8, 82-91	
488	Extended pairwise local alignment of wild card DNA/RNA sequences using dynamic programming. 2015 , 85, 3-13	2
487	Sweating the small stuff: adequacy and accuracy in sweat chloride determination. 2015 , 48, 443-7	10
486	42-year-old man with asthma symptoms and recurrent bronchitis. 2015 , 90, 527-31	

485	Cystic fibrosis (cf) and ovarian reserve: A cross-sectional study examining serum anti-mullerian hormone (amh) in young women. 2015 , 14, 398-402	16
484	Slower rise of exhaled breath temperature in cystic fibrosis. 2015 , 52, 125-7	3
483	Clinical expression of patients with the D1152H CFTR mutation. 2015 , 14, 447-52	29
482	From lip to lab: salty tasting skin is the main clue that raises clinical suspicion of cystic fibrosis in young infants. 2015 , 104, e210-5	5
481	Early Childhood Risk Factors for Decreased FEV1 at Age Six to Seven Years in Young Children with Cystic Fibrosis. 2015 , 12, 1170-6	21
480	Sweat test practice in pediatric pulmonology after introduction of cystic fibrosis newborn screening. 2015 , 174, 1613-20	6
479	Prolongation of antibiotic treatment for cystic fibrosis pulmonary exacerbations. 2015 , 14, 770-6	31
478	Diagnóstico genético de fibrosis quística mediante la técnica de desnaturalización de ADN a alta resolución (HRM). 2015 , 8, 154-164	
477	Newborn Screening for Cystic Fibrosis in California. 2015 , 136, 1062-72	71
476	ATS Core Curriculum 2015: Part III. Pediatric Pulmonary Medicine. 2015 , 12, 1688-96	1
475	Impact of different etiologies of bronchiectasis on the pulmonary function tests. 2015 , 13, 12-9	12
474	Characterization of Missing Data in Clinical Registry Studies. 2015 , 49, 146-154	9
473	Clinical outcomes after initial pseudomonas acquisition in cystic fibrosis. 2015 , 50, 42-8	49
472	Increasing nontuberculous mycobacteria infection in cystic fibrosis. 2015 , 14, 53-62	93
471	Novel personalized therapies for cystic fibrosis: treating the basic defect in all patients. 2015 , 277, 155-166	64
470	Children and young adults with CF in the USA have better lung function compared with the UK. 2015 , 70, 229-36	41
469	Comprehensive CFTR gene analysis of the French cystic fibrosis screened newborn cohort: implications for diagnosis, genetic counseling, and mutation-specific therapy. 2015 , 17, 108-16	30
468	Body Composition, Inflammation, Physical Exercises and Food Intake in Cystic Fibrosis: Cross-Sectional Study. 2016 , 01,	0

467	Einführung des deutschlandweiten Neugeborenen Screenings für Mukoviszidose. 2016 , 40,	1
466	Pathologies Susceptible to be Targeted for Nonsense Mutation Therapies. 2016 , 77-105	
465	Analysis of the CFTR gene in Venezuelan cystic fibrosis patients, identification of six novel cystic fibrosis-causing genetic variants. 2016 , 9, 33-8	3
464	Gender Differences in Clinical Presentations of Cystic Fibrosis Patients in Azeri Turkish Population. 2016 , 79, 267-273	2
463	Clinical impact of <i>Achromobacter xylosoxidans</i> colonization/infection in patients with cystic fibrosis. 2016 , 49, e5097	12
462	Evaluating Adult Cystic Fibrosis Care in BC: Disparities in Access to a Multidisciplinary Treatment Centre. 2016 , 2016, 8901756	8
461	Assessment of the Microbial Constituents of the Home Environment of Individuals with Cystic Fibrosis (CF) and Their Association with Lower Airways Infections. 2016 , 11, e0148534	19
460	Benign and Deleterious Cystic Fibrosis Transmembrane Conductance Regulator Mutations Identified by Sequencing in Positive Cystic Fibrosis Newborn Screen Children from California. 2016 , 11, e0155624	17
459	CFTR Modulators: Shedding Light on Precision Medicine for Cystic Fibrosis. 2016 , 7, 275	79
458	Smaller Width of the Pancreatic Duct During Secretin-Enhanced Magnetic Resonance Cholangiopancreatography in Pancreatic-Sufficient Cystic Fibrosis Patients. 2016 , 45, 1175-8	1
457	Problem-based learning discussion: Medical treatment of pediatric chronic rhinosinusitis. 2016 , 30, 113-21	5
456	Safety and Efficacy of a Novel Microbial Lipase in Patients with Exocrine Pancreatic Insufficiency due to Cystic Fibrosis: A Randomized Controlled Clinical Trial. <i>Journal of Pediatrics</i> , 2016 , 176, 156-161.e13.6	14
455	Salt depletion syndrome as the initial presentation of cystic fibrosis in a toddler with the rare p.Ala309Gly (A309G) CFTR variant. 2016 , 90, 186-7	
454	Comprehensive and Quantitative Profiling of the Human Sweat Submetabolome Using High-Performance Chemical Isotope Labeling LC-MS. 2016 , 88, 7378-86	30
453	Qualitative dimensions of exertional dyspnea in adults with cystic fibrosis. 2016 , 121, 449-56	9
452	Intragenic CFTR Duplication and 5T/12TG Variant in a Patient with Non-Classic Cystic Fibrosis. 2016 , 6, 38776	1
451	Mukoviszidose. 2016 , 28, 355-375	
450	Pediatric Liver Disease. 2016 , 587-597	

449	Features of Severe Liver Disease With Portal Hypertension in Patients With Cystic Fibrosis. 2016 , 14, 1207-1215.e3	60
448	Chronic cough with normal sweat chloride: Phenotypic descriptions of two rare cystic fibrosis genotypes. 2016 , 17, 17-9	1
447	Niejednoznaczna diagnoza mukowiscydozy u dzieci z pozytywnym wynikiem badania przesiewowego. 2016 , 91, 312-317	
446	The role, yield and cost of paediatric faecal elastase-1 testing. 2016 , 16, 551-4	9
445	The Impact on Genetic Testing of Mutational Patterns of CFTR Gene in Different Clinical Macrocategories of Cystic Fibrosis. 2016 , 18, 554-65	14
444	Improvement in Quality of Life after Therapy for Mycobacterium abscessus Group Lung Infection. A Prospective Cohort Study. 2016 , 13, 40-8	37
443	Respiratory sleep disturbance in children and adolescents with cystic fibrosis. 2016 , 22, 202-8	9
442	The Cystic Fibrosis Foundation Patient Registry. Design and Methods of a National Observational Disease Registry. 2016 , 13, 1173-9	180
441	Mukoviszidose. 2016 , 303-312	
440	Pharmacological Chaperones: Design and Development of New Therapeutic Strategies for the Treatment of Conformational Diseases. 2016 , 11, 1471-89	64
439	Forecasting US ivacaftor outcomes and cost in cystic fibrosis patients with the G551D mutation. 2016 , 47, 1697-705	22
438	The benefits of newborn screening for cystic fibrosis: The Canadian experience. 2016 , 15, 302-8	36
437	Handbook of Cystic Fibrosis. 2016 ,	4
436	Diagnosis of Cystic Fibrosis. 2016 , 43-63	1
435	Standardy opieki Europejskiego Towarzystwa Mukowiscydozy: wytyczne i najlepsze praktyki. 2016 , 91, S30-S53	
434	Maintaining mental health and function for the long run in cystic fibrosis. 2016 , 51, S71-S78	24
433	The phospholipid flippase ATP8B1 mediates apical localization of the cystic fibrosis transmembrane regulator. 2016 , 1863, 2280-8	4
432	Editors' Digest - Basic Science A Wearable Sweat Analyzer for Continuous Electrolyte Monitoring. 2016 , 36, 470-1	1

431	Clinical approach to the diagnosis and treatment of cystic fibrosis and CFTR-related disorders. 2016 , 10, 1177-1186	8
430	Pharmacogenetics of cystic fibrosis treatment. 2016 , 17, 1453-63	5
429	Feasibility, tolerability and safety of pediatric hyperpolarized Xe magnetic resonance imaging in healthy volunteers and children with cystic fibrosis. 2016 , 46, 1651-1662	58
428	Feasibility of lung clearance index in a clinical setting in pre-school children. 2016 , 48, 1074-1080	28
427	Sweat chloride concentrations in children with Idiopathic Nephrotic Syndrome. 2016 , 51, 49-52	2
426	Cystic Fibrosis Diagnosis and Newborn Screening. 2016 , 63, 599-615	23
425	Respiratory System Disease. 2016 , 63, 637-59	3
424	Molecular Genetics of Cystic Fibrosis Transmembrane Conductance Regulator: Genotype and Phenotype. 2016 , 63, 585-98	31
423	Phenotypes of California CF Newborn Screen-Positive Children with CFTR 5T Allele by TG Repeat Length. 2016 , 20, 496-503	12
422	Nasal potential difference outcomes support diagnostic decisions in cystic fibrosis. 2016 , 15, 579-82	3
421	Sources of Variation in Sweat Chloride Measurements in Cystic Fibrosis. 2016 , 194, 1375-1382	46
420	Chronic Rhinosinusitis in Patients with Cystic Fibrosis. 2016 , 4, 605-12	40
419	The 1-Minute Sit-to-Stand Test in Adults With Cystic Fibrosis: Correlations With Cardiopulmonary Exercise Test, 6-Minute Walk Test, and Quadriceps Strength. 2016 , 61, 1620-1628	27
418	Disrupted progression of the intestinal microbiota with age in children with cystic fibrosis. 2016 , 6, 24857	50
417	Personalized medicine in cystic fibrosis: genistein supplementation as a treatment option for patients with a rare S1045Y-CFTR mutation. 2016 , 311, L364-74	7
416	Quality of sweat test (ST) based on the proportion of sweat sodium (Na) and sweat chloride (Cl) as diagnostic parameter of cystic fibrosis: are we on the right way?. 2016 , 11, 103	3
415	Comparison of Nasal Potential Difference and Intestinal Current Measurements as Surrogate Markers for CFTR Function. 2016 , 63, e92-e97	8
414	Cystic fibrosis screen positive, inconclusive diagnosis. 2016 , 22, 617-22	12

413	Refining the continuum of CFTR-associated disorders in the era of newborn screening. 2016 , 89, 539-49	24
412	Expiratory Flow Limitation for Monitoring Cystic Fibrosis. Ready for the Starting Gun?. 2016 , 13, 770-1	
411	Variability of gait speed during six minutes walking test in COPD and cystic fibrosis patients. 2016 , 49, 36-40	6
410	The relationship between cardiac hemodynamics and exercise tolerance in cystic fibrosis. 2016 , 45, 283-90	7
409	Clinical Sensitivity of Cystic Fibrosis Mutation Panels in a Diverse Population. 2016 , 37, 201-8	20
408	Abbreviation modalities of nitrogen multiple-breath washout tests in school children with obstructed lung disease. 2016 , 51, 624-32	17
407	Comparison of innate immune responses towards rhinovirus infection of primary nasal and bronchial epithelial cells. 2016 , 21, 304-12	19
406	Discovery of novel plasma protein biomarkers to predict imminent cystic fibrosis pulmonary exacerbations using multiple reaction monitoring mass spectrometry. 2016 , 71, 216-22	29
405	Safety, pharmacokinetics, and pharmacodynamics of ivacaftor in patients aged 2-5 years with cystic fibrosis and a CFTR gating mutation (KIWI): an open-label, single-arm study. 2016 , 4, 107-15	191
404	The impact of a national population carrier screening program on cystic fibrosis birth rate and age at diagnosis: Implications for newborn screening. 2016 , 15, 460-6	20
403	Cystic Fibrosis: A Review of Associated Phenotypes, Use of Molecular Diagnostic Approaches, Genetic Characteristics, Progress, and Dilemmas. 2016 , 18, 3-14	51
402	The cystic fibrosis microbiome in an ecological perspective and its impact in antibiotic therapy. 2016 , 100, 1163-1181	26
401	Diagnostic Testing in Cystic Fibrosis. 2016 , 37, 31-46	9
400	The Spectrum of CFTR Variants in Nonwhite Cystic Fibrosis Patients: Implications for Molecular Diagnostic Testing. 2016 , 18, 39-50	53
399	Clinical Phenotypes and Genotypic Spectrum of Cystic Fibrosis in Chinese Children. <i>Journal of Pediatrics</i> , 2016 , 171, 269-76.e1	3.6 25
398	Reversible airway obstruction in cystic fibrosis: Common, but not associated with characteristics of asthma. 2016 , 15, 652-9	12
397	CFTR and Cystic Fibrosis. 2016 , 519-552	3
396	Epidemiology of Cystic Fibrosis. 2016 , 37, 1-8	61

395	Measurement of fecal elastase improves performance of newborn screening for cystic fibrosis. 2016 , 15, 313-7			11
394	Diagnosis of Adult Patients with Cystic Fibrosis. 2016 , 37, 47-57			16
393	Question 7: For an infant with an equivocal sweat chloride following newborn screening, how likely is a diagnosis of cystic fibrosis?. 2016 , 20, 48-50			2
392	A semi-blinded study comparing 2 methods of measuring nasal potential difference: Subcutaneous needle versus dermal abrasion. 2016 , 15, 60-6			3
391	Screening for cystic fibrosis in New York State: considerations for algorithm improvements. 2016 , 175, 181-93			13
390	Cystic Fibrosis. 2016 , 822-852.e17			4
389	Cost-of-illness analysis and regression modeling in cystic fibrosis: a retrospective prevalence-based study. 2017 , 18, 73-82			7
388	mRNA-based detection of rare CFTR mutations improves genetic diagnosis of cystic fibrosis in populations with high genetic heterogeneity. 2017 , 91, 476-481			6
387	Cystic fibrosis newborn screening programs: implications of the CFTR variant spectrum in nonwhite patients. 2017 , 19, 36-44			17
386	The correlation between age and sweat chloride levels in sweat tests. 2017 , 23, 227-230			4
385	Biological variability of the sweat chloride in diagnostic sweat tests: A retrospective analysis. 2017 , 16, 30-35			20
384	Applying Cystic Fibrosis Transmembrane Conductance Regulator Genetics and CFTR2 Data to Facilitate Diagnoses. <i>Journal of Pediatrics</i> , 2017 , 181S, S27-S32.e1	3.6		43
383	Cystic Fibrosis Transmembrane Conductance Regulator-Related Metabolic Syndrome and Cystic Fibrosis Screen Positive, Inconclusive Diagnosis. <i>Journal of Pediatrics</i> , 2017 , 181S, S45-S51.e1	3.6		58
382	Das Mukoviszidosescreening wird in Deutschland eingeführt. 2017 , 165, 49-54			2
381	Diagnosis of Cystic Fibrosis in Nonscreened Populations. <i>Journal of Pediatrics</i> , 2017 , 181S, S52-S57.e2	3.6		37
380	Predicting Severity of Disease-Causing Variants. 2017 , 38, 357-364			23
379	Socioeconomic Status, Smoke Exposure, and Health Outcomes in Young Children With Cystic Fibrosis. 2017 , 139,			37
378	Introduction to "Cystic Fibrosis Foundation Consensus Guidelines for Diagnosis of Cystic Fibrosis". <i>Journal of Pediatrics</i> , 2017 , 181S, S1-S3	3.6		3

377	Diagnosis of Cystic Fibrosis: Consensus Guidelines from the Cystic Fibrosis Foundation. <i>Journal of Pediatrics</i> , 2017 , 181S, S4-S15.e1	3.6	368
376	Role of CFTR mutation analysis in the diagnostic algorithm for cystic fibrosis. 2017 , 13, 129-135		9
375	Cystic Fibrosis Diagnostic Challenges over 4 Decades: Historical Perspectives and Lessons Learned. <i>Journal of Pediatrics</i> , 2017 , 181S, S16-S26	3.6	21
374	[Management of infants whose diagnosis is inconclusive at neonatal screening for cystic fibrosis]. 2017 , 24, 401-414		2
373	Genotype-phenotype correlation and functional studies in patients with cystic fibrosis bearing CFTR complex alleles. 2017 , 54, 224-235		41
372	Vitamin E supplementation in people with cystic fibrosis. 2017 , 3, CD009422		6
371	Diagnosis of Cystic Fibrosis in Screened Populations. <i>Journal of Pediatrics</i> , 2017 , 181S, S33-S44.e2	3.6	60
370	High-Throughput Screening for Readthrough Modulators of CFTR PTC Mutations. 2017 , 22, 315-324		19
369	Clinical Outcomes Associated with <i>Achromobacter</i> Species Infection in Patients with Cystic Fibrosis. 2017 , 14, 1412-1418		22
368	Biological Variation of Chloride and Sodium in Sweat Obtained by Pilocarpine Iontophoresis in Adults: How Sure are You About Sweat Test Results?. 2017 , 195, 241-246		8
367	A multiple reader scoring system for Nasal Potential Difference parameters. 2017 , 16, 573-578		6
366	Feasibility and normal values of an integrated conductivity (Nanoduct) sweat test system in healthy newborns. 2017 , 16, 465-470		3
365	The importance of functional tests to assess the effect of a new variant when genotype-phenotype correlation is not possible. 2017 , 5, 658-663		4
364	Age-dependent variation of fecal calprotectin in cystic fibrosis and healthy children. 2017 , 16, 631-636		30
363	CFTR-dependent chloride efflux in cystic fibrosis mononuclear cells is increased by ivacaftor therapy. 2017 , 52, 900-908		9
362	Utilization Management in the Clinical Laboratory and Other Ancillary Services. 2017 ,		1
361	Soft, skin-mounted microfluidic systems for measuring secretory fluidic pressures generated at the surface of the skin by eccrine sweat glands. 2017 , 17, 2572-2580		93
360	The HDAC inhibitor SAHA does not rescue CFTR membrane expression in Cystic Fibrosis. 2017 , 88, 124-132		10

359	Diagnosis and Treatment of Cystic Fibrosis: A (Not-so) Simple Recessive Condition. 2017 , 5, 91-99		1
358	Multisystem Imaging Findings of Cystic Fibrosis in Adults: Recognizing Typical and Atypical Patterns of Disease. 2017 , 209, 3-18		10
357	The diagnosis of cystic fibrosis. 2017 , 46, e97-e108		37
356	New approach for cystic fibrosis diagnosis based on chloride/potassium ratio analyzed in non-invasively obtained skin-wipe sweat samples by capillary electrophoresis with contactless conductometric detection. 2017 , 409, 3507-3514		15
355	Psychosocial Response to Uncertain Newborn Screening Results for Cystic Fibrosis. <i>Journal of Pediatrics</i> , 2017 , 184, 165-171.e1	3.6	19
354	Cystic Fibrosis Transmembrane Regulator Modulators: Implications for the Management of Depression and Anxiety in Cystic Fibrosis. 2017 , 58, 343-354		22
353	Long-term clinical outcomes of 'Prairie Epidemic Strain' infection in adults with cystic fibrosis. 2017 , 72, 333-339		11
352	Survival Comparison of Patients With Cystic Fibrosis in Canada and the United States: A Population-Based Cohort Study. 2017 , 166, 537-546		107
351	Effect of pulmonary exacerbations treated with oral antibiotics on clinical outcomes in cystic fibrosis. 2017 , 72, 327-332		38
350	Automated detection of circular marker particles in synchrotron phase contrast X-ray images of live mouse nasal airways for mucociliary transit assessment. 2017 , 73, 57-68		7
349	Multiparameter Single Cell Profiling of Airway Inflammatory Cells. 2017 , 92, 12-20		12
348	Interventions for promoting participation in shared decision-making for children and adolescents with cystic fibrosis. 2017 ,		1
347	Re KOM endacje P ostępow A nia w mukowi S cydozie (cystic fibrosis ; CF) dla lekarzy Podstawowej Opieki Zdrowotnej [KOMPAS CF [cz]]. 2017 , 92, 431-445		
346	Cas clinique n° 3 : Bilan Biologique de dilatations des bronches. 2017 , 9, 21-25		
345	Epidemiology of Rare Lung Diseases: The Challenges and Opportunities to Improve Research and Knowledge. 2017 , 1031, 419-442		6
344	Forecasting the Long-Term Clinical and Economic Outcomes of Lumacaftor/Ivacaftor in Cystic Fibrosis Patients with Homozygous phe508del Mutation. 2017 , 20, 1329-1335		8
343	Neugeborenencreening 2020. 2017 , 165, 216-225		6
342	Nonocclusive Sweat Collection Combined with Chemical Isotope Labeling LC-MS for Human Sweat Metabolomics and Mapping the Sweat Metabolomes at Different Skin Locations. 2017 , 89, 7847-7851		22

341	Cystic Fibrosis. 2017 , 715-730		
340	Molecular Diagnosis of Cystic Fibrosis. 2017 , 235-243		
339	Cystic Fibrosis. 2017 , 208-210		1
338	Secretin-stimulated MRI assessment of exocrine pancreatic function in patients with cystic fibrosis and healthy controls. 2017 , 42, 890-899		11
337	Differences in Outcomes between Early and Late Diagnosis of Cystic Fibrosis in the Newborn Screening Era. <i>Journal of Pediatrics</i> , 2017 , 181, 137-145.e1	3.6	30
336	Reduced β Cell Secretory Capacity in Pancreatic-Insufficient, but Not Pancreatic-Sufficient, Cystic Fibrosis Despite Normal Glucose Tolerance. <i>Diabetes</i> , 2017 , 66, 134-144	0.9	39
335	Cancer risk among lung transplant recipients with cystic fibrosis. 2017 , 16, 91-97		31
334	Prevalence of elevated liver enzymes in children with cystic fibrosis diagnosed by newborn screen. 2017 , 16, 139-145		26
333	Cystic fibrosis: a clinical view. 2017 , 74, 129-140		117
332	Differences in gene mutations between Chinese and Caucasian cystic fibrosis patients. 2017 , 52, E11-E14		13
331	Longitudinal study of <i>Stenotrophomonas maltophilia</i> antibody levels and outcomes in cystic fibrosis patients. 2017 , 16, 58-63		11
330	Systemic and Odontogenic Etiologies in Chronic Rhinosinusitis. 2017 , 50, 95-111		14
329	Refractory Chronic Rhinosinusitis with Nasal Polyposis. 2017 , 50, 61-81		11
328	Impact of <i>Pseudomonas aeruginosa</i> Infection on Respiratory Muscle Function in Adult Cystic Fibrosis Patients. 2017 , 93, 42-50		4
327	An update on new and emerging therapies for cystic fibrosis. 2017 , 22, 331-346		14
326	What can the CF registry tell us about rare CFTR-mutations? A Belgian study. 2017 , 12, 142		7
325	Cystic Fibrosis: An Overview of the Past, Present, and the Future. 2017 , 219-249		3
324	Thirty Years of Sweat Chloride Testing at One Referral Center. 2017 , 5, 222		8

323	Nutrition and Cystic Fibrosis. 2017 , 911-934	
322	Sweat test and cystic fibrosis: overview of test performance at public and private centers in the state of S̃ Paulo, Brazil. 2017 , 43, 121-128	12
321	Brazilian guidelines for the diagnosis and treatment of cystic fibrosis. 2017 , 43, 219-245	39
320	The involvement of musculoskeletal system and its influence on postural stability in children and young adults with cystic fibrosis. 2017 , 43, 106	5
319	Methicillin-resistant Staphylococcus aureus in cystic fibrosis patients: do we need to care? A cohort study. 2017 , 135, 420-427	5
318	Patient knowledge and pulmonary medication adherence in adult patients with cystic fibrosis. 2017 , 11, 691-698	10
317	Pediatric and Adult Recommendations Vary for Sibling Testing in Cystic Fibrosis. 2018 , 27, 1049-1054	3
316	Assessment of pulmonary structure-function relationships in young children and adolescents with cystic fibrosis by multivolume proton-MRI and CT. 2018 , 48, 531-542	12
315	ECFS best practice guidelines: the 2018 revision. 2018 , 17, 153-178	276
314	Probiotics for people with cystic fibrosis. 2018 ,	3
313	Cystic fibrosis: a model for precision medicine. 2018 , 3, 107-117	1
312	A European regulatory perspective on cystic fibrosis: current treatments, trends in drug development and translational challenges for CFTR modulators. 2018 , 27,	11
311	Skin-interfaced systems for sweat collection and analytics. 2018 , 4, eaar3921	217
310	How to Manage Antibiotic Allergy in Cystic Fibrosis? Epidemiologic, Diagnostic, and Therapeutic Aspects. 2018 , 5, 74-102	
309	Liver disease in patients with cystic fibrosis. 2018 , 34, 146-151	22
308	Advances in the Diagnosis and Management of Cystic Fibrosis in the Genomic Era. 2018 , 64, 898-908	8
307	The Role of Multidetector Computed Tomography and the Forced Oscillation Technique in Assessing Lung Damage in Adults With Cystic Fibrosis. 2018 , 63, 430-440	4
306	Cystic Fibrosis (CFTR)-Associated Pancreatic Disease. 2018 , 391-396	

305	May the new suggested lower borderline limit of sweat chloride impact the diagnostic process for cystic fibrosis?. <i>Journal of Pediatrics</i> , 2018 , 194, 261-262	3.6	2
304	Secretin-stimulated ultrasound estimation of pancreatic secretion in cystic fibrosis validated by magnetic resonance imaging. 2018 , 28, 1495-1503		4
303	The Human Genome. 2018 , 121-134		
302	Anti-IgE therapy for allergic bronchopulmonary aspergillosis in people with cystic fibrosis. 2018 , 3, CD010288		3
301	Real-time exhaled breath analysis in patients with cystic fibrosis and controls. 2018 , 12, 036013		16
300	Nutritional Status in the First 2 Years of Life in Cystic Fibrosis Diagnosed by Newborn Screening. 2018 , 67, 123-130		13
299	Changing Rates of Chronic <i>Pseudomonas aeruginosa</i> Infections in Cystic Fibrosis: A Population-Based Cohort Study. 2018 , 67, 1089-1095		23
298	Cystic fibrosis in the era of precision medicine. 2018 , 25, 64-72		17
297	Multiple reaction monitoring mass spectrometry to identify novel plasma protein biomarkers of treatment response in cystic fibrosis pulmonary exacerbations. 2018 , 17, 333-340		5
296	Long-term intestinal obstruction sequelae and growth in children with cystic fibrosis operated for meconium ileus: expectancies and surprises. 2018 , 53, 1504-1508		9
295	Prevalence and characteristics of chronic kidney disease among Danish adults with cystic fibrosis. 2018 , 17, 478-483		12
294	Age-related levels of fecal M2-pyruvate kinase in children with cystic fibrosis and healthy children 0 to 10years old. 2018 , 17, 109-113		13
293	Cystic Fibrosis Newborn Screening in Portugal: PAP Value in Populations with Stringent Rules for Genetic Studies. 2018 , 4, 22		9
292	Comparaçã entre a evoluçã de prãescolares com fibrose cãtica identificados por triagem neonatal ou por sintomatologia clãtica. 2018 , 28, 29566		
291	Cystic Fibrosis: A Deadly Disease and the Vast Majority are Unaware of It. 2018 , 42, 105-107		1
290	Quality of life amongst adolescents and young adults with cystic fibrosis: correlations with clinical outcomes. 2018 , 73, e427		4
289	Molecular and Functional Basis of Cystic Fibrosis in Indian Patients: Genetic, Diagnostic and Therapeutic Implications. 2018 , 54, 216-230		
288	Molecular basis of cystic fibrosis: from bench to bedside. 2018 , 6, 334		23

287	Standardized clinical criteria and sweat test combined as a tool to diagnose Cystic Fibrosis. 2018 , 4, e01050	2
286	Cystic Fibrosis. 2018 , 195-213	0
285	Cystic Fibrosis: Clinical Phenotypes in Children and Adolescents. 2018 , 21, 306-314	11
284	Foundations of Respiratory Medicine. 2018 ,	
283	[Spirometric characterization of cystic fibrosis patients]. 2018 , 89, 332-338	1
282	Clinical Characteristics and Predictors of Reduced Survival for Adult-diagnosed Cystic Fibrosis. Analysis of the Canadian CF Registry. 2018 , 15, 1177-1185	14
281	Wireless fluorimeter for mobile and low cost chemical sensing: A paper based chloride assay. 2018 , 275, 230-236	14
280	Contrast-enhanced ultrasonography of the pancreas shows impaired perfusion in pancreas insufficient cystic fibrosis patients. 2018 , 18, 14	5
279	Performance Evaluation of a New Coulometric Endpoint Method in Sweat Testing and Its Comparison With Classic Gibson&Cooke and Chloridometer Methods in Cystic Fibrosis. 2018 , 6, 133	2
278	Sonographic pancreas echogenicity in cystic fibrosis compared to exocrine pancreatic function and pancreas fat content at Dixon-MRI. 2018 , 13, e0201019	5
277	Alpha-1 Antitrypsin Deficiency and Other Metabolic Liver Diseases. 2018 , 269-281	
276	The Potential of Biomarkers in the Early Detection of Pressure Ulcers. 2018 , 1-15	6
275	Clinical course and significance of nontuberculous mycobacteria and its subtypes in cystic fibrosis. 2018 , 18, 311	4
274	Overall and differentiated sensory responses to cardiopulmonary exercise test in patients with cystic fibrosis: kinetics and ability to predict peak oxygen uptake. 2018 , 118, 2007-2019	3
273	Microbiome characteristics of induced sputum compared to bronchial fluid and upper airway samples. 2018 , 53, 921-928	14
272	Fitness and lung function in children with primary ciliary dyskinesia and cystic fibrosis. 2018 , 139, 79-85	9
271	Meconium Ileus. 2018 , 739-757	
270	Is sweat testing for cystic fibrosis feasible in patients with down syndrome?. 2018 , 18, 8	

269	S737F is a new CFTR mutation typical of patients originally from the Tuscany region in Italy. 2018 , 44, 2	12
268	Dietary intake of energy-dense, nutrient-poor and nutrient-dense food sources in children with cystic fibrosis. 2018 , 17, 804-810	31
267	Sinonasal computed tomography in pediatric cystic fibrosis: do we know the indications?. 2018 , 113, 204-207	1
266	Comparison of the upper and lower airway microbiota in children with chronic lung diseases. 2018 , 13, e0201156	13
265	Liver Disease in Cystic Fibrosis. 2018 , 143-150	
264	ECeell secretory defects are present in pancreatic insufficient cystic fibrosis with 1-hour oral glucose tolerance test glucose ≥ 55 mg/dL. 2018 , 19, 1173-1182	19
263	Is an FEV of 80% predicted a normal spirometry in cystic fibrosis children and adults?. 2018 , 12, 2397-2403	5
262	Genetics and Pathophysiology of Cystic Fibrosis. 2019 , 757-768.e6	3
261	Miscellaneous Airway Diseases. 2019 , 113-125	
260	EVALUATION OF NUTRITIONAL STATUS IN PATIENTS WITH CYSTIC FIBROSIS ACCORDING TO AGE GROUP. 2019 , 37, 58-64	1
259	Diagnostic evaluation of bronchiectasis. 2019 , 1, 100006	0
258	Identification of 99% of CFTR gene mutations in Bulgarian-, Bulgarian Turk-, and Roma cystic fibrosis patients. 2019 , 7, e696	3
257	Targeting DNAJB9, a novel ER luminal co-chaperone, to rescue E508-CFTR. 2019 , 9, 9808	10
256	Atypical presentation of cystic fibrosis at 70 years of age. 2019 , 12,	
255	Applications of biomarkers for different purposes in drug development. 2019 , 11-40	1
254	Elexacaftor-Tezacaftor-Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele. 2019 , 381, 1809-1819	504
253	Adiponectin Expression Is Modulated by Long-Term Physical Activity in Adult Patients Affected by Cystic Fibrosis. 2019 , 2019, 2153934	8
252	Social Work and Genetics. 2019 , 499-534	

251	[Follow-up protocol of patients with cystic fibrosis diagnosed by newborn screening]. 2019 , 90, 251.e1-251.e103	
250	Soft, Skin-Integrated Multifunctional Microfluidic Systems for Accurate Colorimetric Analysis of Sweat Biomarkers and Temperature. 2019 , 4, 379-388	134
249	The Genetics of Pneumothorax. 2019 , 199, 1344-1357	27
248	Airway colonisation by <i>Candida</i> and <i>Aspergillus</i> species in Iranian cystic fibrosis patients. 2019 , 62, 434-440	7
247	Effects of inspiratory muscle training on postural stability, pulmonary function and functional capacity in children with cystic fibrosis: A randomised controlled trial. 2019 , 148, 24-30	6
246	Decreased Fecal Calprotectin Levels in Cystic Fibrosis Patients After Antibiotic Treatment for Respiratory Exacerbation. 2019 , 68, 282-284	11
245	Extent of rescue of F508del-CFTR function by VX-809 and VX-770 in human nasal epithelial cells correlates with SNP rs7512462 in SLC26A9 gene in F508del/F508del Cystic Fibrosis patients. 2019 , 1865, 1323-1331	17
244	Herbal dry extract BNO 1011 improves clinical and mucociliary parameters in a rabbit model of chronic rhinosinusitis. 2019 , 9, 629-637	8
243	A real world evaluation of the long-term efficacy of strategies to prevent chronic <i>Pseudomonas aeruginosa</i> pulmonary infection in children with cystic fibrosis. 2019 , 85, 92-97	2
242	Cystic Fibrosis. 2019 , 235-252	
241	Deletion of exons 16-17b of CFTR is frequently identified in Korean patients with cystic fibrosis. 2019 , 62, 103681	6
240	Cas clinique n° 1 : Prise en charge d'une mucoviscidose : «chaque mutation son traitement ?». 2019 , 11, 3-9	
239	An open-label extension study of ivacaftor in children with CF and a CFTR gating mutation initiating treatment at age 2-5 years (KLIMB). 2019 , 18, 838-843	44
238	Cystic Fibrosis Transmembrane Conductance Regulator: A Possible New Target for Photodynamic Therapy Enhances Wound Healing. 2019 , 8, 476-486	6
237	Final evidence report as part of preparatory work for the setting of Dietary Reference Values for sodium and chloride. 2019 , 16, 692E	1
236	Pathogen acquisition in patients with cystic fibrosis receiving ivacaftor or lumacaftor/ivacaftor. 2019 , 54, 1200-1208	16
235	Impact of Intermediate Cystic Fibrosis Classification on Parents' Perceptions of Child Vulnerability and Protectiveness. 2019 , 25, 287-313	0
234	Assessment of stability and fluctuations of cultured lower airway bacterial communities in people with cystic fibrosis. 2019 , 18, 808-816	12

233	Skin-Mountable Biosensors and Therapeutics: A Review. 2019 , 21, 299-323	27
232	Oral Azithromycin and Response to Pulmonary Exacerbations Treated with Intravenous Tobramycin in Children with Cystic Fibrosis. 2019 , 16, 861-867	7
231	Change in lung clearance index with microbiological status in children with cystic fibrosis. 2019 , 54, 729-736	9
230	Liver Failure in a Chinese Cystic Fibrosis Child With Homozygous R553X Mutation. 2019 , 7, 36	5
229	Passive sweat collection and colorimetric analysis of biomarkers relevant to kidney disorders using a soft microfluidic system. 2019 , 19, 1545-1555	91
228	Oral Azithromycin Use and the Recovery of Lung Function from Pulmonary Exacerbations Treated with Intravenous Tobramycin or Colistimethate in Adults with Cystic Fibrosis. 2019 , 16, 853-860	7
227	Follow-up protocol of patients with cystic fibrosis diagnosed by newborn screening. 2019 , 90, 251.e1-251.e10	
226	Cystic fibrosis dyslipidaemia: A cross-sectional study. 2019 , 18, 566-571	6
225	Bone mineral density in cystic fibrosis patients using low-dose chest computed tomography: a pilot study. 2019 , 53,	0
224	Computed Tomography Description of the Uncinate Process Angulation in Patients With Cystic Fibrosis and Comparison With Primary Ciliary Dyskinesia, Nasal Polyposis, and Controls. 2019 , 98, 89-93	3
223	Self-powered smart patch for sweat conductivity monitoring. 2019 , 5, 3	30
222	Size-adjusted muscle power and muscle metabolism in patients with cystic fibrosis are equal to healthy controls - a case control study. 2019 , 19, 269	2
221	Unsolved severe chronic rhinosinusitis elucidated by extensive genotyping. 2019 , 7, 2128-2134	1
220	Interventions for promoting participation in shared decision-making for children and adolescents with cystic fibrosis. 2019 , 5, CD012578	5
219	Gut Microbiota in Children With Cystic Fibrosis: A Taxonomic and Functional Dysbiosis. 2019 , 9, 18593	28
218	Patients with Idiopathic Pulmonary Nontuberculous Mycobacterial Disease Have Normal Th1/Th2 Cytokine Responses but Diminished Th17 Cytokine and Enhanced Granulocyte-Macrophage Colony-Stimulating Factor Production. 2019 , 6, ofz484	7
217	Aspergillus terreus Causing Probable Invasive Aspergillosis in a Patient with Cystic Fibrosis. 2019 , 184, 151-154	2
216	The increasing challenge of genetic counseling for cystic fibrosis. 2019 , 18, 167-174	8

215	Higher Interleukin-7 serum concentrations in patients with cystic fibrosis correlate with impaired lung function. 2019 , 18, 71-77	1
214	Innovative Therapies for Cystic Fibrosis: The Road from Treatment to Cure. 2019 , 23, 263-279	7
213	Comparison of two sweat test systems for the diagnosis of cystic fibrosis in newborns. 2019 , 54, 264-272	9
212	Identification of molecular signatures of cystic fibrosis disease status with plasma-based functional genomics. 2019 , 51, 27-41	8
211	The role of small intestinal bacterial overgrowth in cystic fibrosis: a randomized case-controlled clinical trial with rifaximin. 2019 , 54, 261-270	7
210	IVACAFTOR restores FGF19 regulated bile acid homeostasis in cystic fibrosis patients with an S1251N or a G551D gating mutation. 2019 , 18, 286-293	13
209	Optimal data-driven policies for disease screening under noisy biomarker measurement. 2020 , 52, 166-180	1
208	Nasal potential difference in suspected cystic fibrosis patients with 5T polymorphism. 2020 , 19, 627-631	1
207	Cystic Fibrosis. 2020 , 285-339	1
206	244th ENMC international workshop: Newborn screening in spinal muscular atrophy May 10-12, 2019, Hoofddorp, The Netherlands. 2020 , 30, 93-103	29
205	The Use of Ultrasound as a Tool to Evaluate Pulmonary Disease in Cystic Fibrosis. 2020 , 65, 293-303	4
204	Cystic fibrosis in black African children in South Africa: a case control study. 2020 , 19, 540-545	8
203	Phenotype of children with inconclusive cystic fibrosis diagnosis after newborn screening. 2020 , 55, 918-928	15
202	Targeted and Untargeted Proteomics Approaches in Biomarker Development. 2020 , 20, e1900029	33
201	Skin-interfaced soft microfluidic systems with modular and reusable electronics for capacitive sensing of sweat loss, rate and conductivity. 2020 , 20, 4391-4403	9
200	Sweat chloride assay by inductively coupled plasma mass spectrometry: a confirmation test for cystic fibrosis diagnosis. 2020 , 412, 6909-6916	6
199	Untargeted Metagenomic Investigation of the Airway Microbiome of Cystic Fibrosis Patients with Moderate-Severe Lung Disease. 2020 , 8,	14
198	Lung function deterioration in school children with cystic fibrosis. 2020 , 55, 3030-3038	0

197	Cystic fibrosis: Physiopathology and the latest pharmacological treatments. 2020 , 162, 105267	5
196	Cystic Fibrosis Diagnosed Using Indigenously Wrapped Sweating Technique: First Large-Scale Study Reporting Socio-Demographic, Clinical, and Laboratory Features among the Children in Bangladesh A Lower Middle Income Country. 2020 , 7, 2333794X20967585	1
195	Do pulmonary and extrapulmonary features differ among cystic fibrosis, primary ciliary dyskinesia, and healthy children?. 2020 , 55, 3067-3073	3
194	Autophagy Augmentation to Alleviate Immune Response Dysfunction, and Resolve Respiratory and COVID-19 Exacerbations. 2020 , 9,	20
193	Vitamin E supplementation in people with cystic fibrosis. 2020 , 9, CD009422	1
192	Biomarkers: Opportunities and Challenges for Drug Development in the Current Regulatory Landscape. 2020 , 15, 1177271920974652	14
191	Recent Progress in Wearable Biosensors: From Healthcare Monitoring to Sports Analytics. 2020 , 10,	28
190	Assessment of Distinct Electrophysiological Parameters in Rectal Biopsies for the Choice of the Best Diagnosis/Prognosis Biomarkers for Cystic Fibrosis. 2020 , 11, 604580	4
189	Phenotypes of Chronic Rhinosinusitis. 2020 , 8, 1505-1511	15
188	Management of Sinusitis in the Cystic Fibrosis Patient. 2020 , 40, 371-383	3
187	Pediatric Versus Adult Chronic Rhinosinusitis. 2020 , 20, 29	6
186	Secretin-Stimulated Magnetic Resonance Imaging Reveals Variable Diagnostic Accuracy According to Etiology in Pancreatic Disease. 2020 , 49, 361-367	2
185	Clinical, genetic and microbiological characterization of pediatric patients with cystic fibrosis in a public Hospital in Ecuador. 2020 , 20, 111	1
184	Cystic Fibrosis: A Simple and Customized Strategy for Genetic Screening Able to Detect Over 90% of Identified Mutated Alleles in Brazilian Newborns. 2020 , 24, 315-325	
183	Pediatric laboratory medicine. 2020 , 507-518	
182	Diagnostic performance and role of the contrast enema for low intestinal obstruction in neonates. 2020 , 36, 1093-1101	4
181	Methods for detecting toxic α -synuclein species as a biomarker for Parkinson's disease. 2020 , 57, 291-307	6
180	Probiotics for people with cystic fibrosis. 2020 , 1, CD012949	12

179	Skin wipe test: A simple, inexpensive, and fast approach in the diagnosis of cystic fibrosis. 2020 , 55, 1653-1660	6
178	Processing Newborn Bloodspot Screening Results for CF. 2020 , 6, 25	1
177	Newborn Screening for Cystic Fibrosis in Russia: A Catalyst for Improved Care. 2020 , 6, 34	0
176	Dried Blood Spot-Based Metabolomic Profiling in Adults with Cystic Fibrosis. 2020 , 19, 2346-2357	9
175	Evaluating the Alimentary and Respiratory Tracts in Health and disease (EARTH) research programme: a protocol for prospective, longitudinal, controlled, observational studies in children with chronic disease at an Australian tertiary paediatric hospital. 2020 , 10, e033916	1
174	Females with cystic fibrosis have a larger decrease in sweat chloride in response to lumacaftor/ivacaftor compared to males. 2021 , 20, e7-e11	8
173	Longitudinal Assessment of Patients With Cystic Fibrosis Lung Disease With Multivolume Noncontrast MRI and Spirometry. 2021 , 53, 1570-1580	0
172	Early acquisition and conversion of <i>Pseudomonas aeruginosa</i> in Hispanic youth with cystic fibrosis in the United States. 2021 , 20, 424-431	2
171	Safety and efficacy of the cystic fibrosis transmembrane conductance regulator potentiator icenticaftor (QBW251). 2021 , 20, 250-256	7
170	Implementing a tracking system for confirmatory diagnostic results after positive newborn screening for cystic fibrosis-implications for process quality and patient care. 2021 , 180, 1145-1155	1
169	Motor repertoire is age-inadequate in infants with cystic fibrosis. 2021 , 89, 1291-1296	3
168	Fighting diagnostic confirmation bias: Cystic fibrosis, allergic bronchopulmonary aspergillus, or both?. 2021 , 9, 1379-1382	0
167	Prognosis-Based Early Intervention Strategies to Resolve Exacerbation and Progressive Lung Function Decline in Cystic Fibrosis. 2021 , 11,	1
166	Severe Genotype, Pancreatic Insufficiency and Low Dose of Pancreatic Enzymes Associate with Abnormal Serum Sterol Profile in Cystic Fibrosis. 2021 , 11,	0
165	Cystic Fibrosis. 2021 , 42, 55-67	5
164	An on-skin platform for wireless monitoring of flow rate, cumulative loss and temperature of sweat in real time. 2021 , 4, 302-312	33
163	A Novel Cystic Fibrosis Gene Mutation C.4242+1G>C in an Omani Patient: A Case Report. 2021 , 36, e243	0
162	The correlation between 6-min walk test and respiratory parameters in children with cystic fibrosis. 2021 , 1	0

161	Printed Iontophoretic-Integrated Wearable Microfluidic Sweat-Sensing Patch for On-Demand Point-Of-Care Sweat Analysis. 2021 , 6, 2000910	8
160	A pilot study of cystic fibrosis exacerbation response phenotypes reveals contrasting serum and sputum iron trends. 2021 , 11, 4897	0
159	Case Report: White Colored Stool: An Early Sign of Cystic Fibrosis in Infants. 2021 , 9, 656584	0
158	CFTR-associated Pancreatic Disease. 2021 , 369-378	
157	Review of clinical guidelines [Cystic fibrosis]2020. 2021 , 31, 135-146	6
156	Self-Powered Point-of-Care Device for Galvanic Cell-Based Sample Concentration Measurement. 2021 , 21,	3
155	Dedicated low-cost spectrophotometer to assist in cystic fibrosis diagnosis. 2021 , 37, 329-337	0
154	Bone Cells Differentiation: How CFTR Mutations May Rule the Game of Stem Cells Commitment?. 2021 , 9, 611921	2
153	The Correlation of Health-Related Quality of Life with Cystic Fibrosis Severity Markers in Chest CT Scan and 6-Minute Walk Test: A Cross-Sectional Study. 2021 , 1	0
152	Effect of Sitagliptin on Islet Function in Pancreatic Insufficient Cystic Fibrosis With Abnormal Glucose Tolerance. 2021 , 106, 2617-2634	3
151	Sweat Testing and Recent Advances. 2021 , 9, 649904	1
150	Stretchable and Superwetable Colorimetric Sensing Patch for Epidermal Collection and Analysis of Sweat. 2021 , 6, 2261-2269	17
149	Reduced neutrophil elastase inhibitor elafin and elevated transforming growth factor- β are linked to inflammatory response in sputum of cystic fibrosis patients with. 2021 , 7,	2
148	Colonic Transit Time and Fecal Impaction in Children and Adolescents With Cystic Fibrosis-associated Constipation. 2021 , 73, 319-324	1
147	Two Years of Newborn Screening for Cystic Fibrosis in North Macedonia: First Experience. 2021 , 24, 41-46	1
146	Microbial Cystic Fibrosis.	
145	Dialogs in the assessment of neonatal cholestatic liver disease. 2021 , 112, 102-115	0
144	Preclinical atherosclerosis in cystic fibrosis: Two distinct presentations are related to pancreatic status. 2021 ,	0

143	CFTR-mediated monocyte-macrophage dysfunction revealed by cystic fibrosis proband- parent comparisons.	
142	Clinical Characteristics Associated With Lung Function Decline in Individuals With Adult-Diagnosed Cystic Fibrosis: Contemporary Analysis of the Canadian CF Registry. 2021 , 160, 65-73	
141	Assessment of hospitalization rates, factors associated with hospitalization and in-patient mortality in pediatric patients with cystic fibrosis. 2021 ,	
140	Pharmacometabolomics: A New Horizon in Personalized Medicine.	1
139	Evaluation of anthropometry as an alternative to DXA as predictor of low bone mineral density in children and adolescents with cystic fibrosis. 2021 , 45, 229-235	1
138	Anti-IgE therapy for allergic bronchopulmonary aspergillosis in people with cystic fibrosis. 2021 , 9, CD010288	
137	Protracted Diarrhea. 2021 , 339-349.e4	
136	Nasal potential difference measurements to assess CFTR ion channel activity. 2011 , 741, 69-86	63
135	Cystic Fibrosis. 2016 , 471-485	1
134	Nucleotide-mediated airway clearance. 2011 , 55, 95-138	21
133	Cystic Fibrosis. 2010 , 985-1022	6
132	Electrolytes and Blood Gases. 2012 , 807-835	5
131	Diseases of Infancy and Childhood. 2010 , 447-483	8
130	Cystic Fibrosis. 2015 , 874-885.e3	1
129	Guidelines for the clinical management and follow-up of infants with inconclusive cystic fibrosis diagnosis through newborn screening. 2017 , 24, e1-e14	10
128	Multilocus sequence analysis reveals high genetic diversity in clinical isolates of <i>Burkholderia cepacia</i> complex from India. 2016 , 6, 35769	9
127	Lentiviral-mediated phenotypic correction of cystic fibrosis pigs. 2016 , 1,	56
126	Nasal and sinus problems in cystic fibrosis patients. 48-66	5

125	The Cystic Fibrosis Impact Questionnaire: qualitative development and cognitive evaluation of a new patient-reported outcome instrument to assess the life impacts of cystic fibrosis. 2020 , 4, 36	2
124	Defective CFTR expression and function are detectable in blood monocytes: development of a new blood test for cystic fibrosis. 2011 , 6, e22212	46
123	Normalized T1 magnetic resonance imaging for assessment of regional lung function in adult cystic fibrosis patients--a cross-sectional study. 2013 , 8, e73286	15
122	Optical coherence tomography identifies lower labial salivary gland surface density in cystic fibrosis. 2015 , 10, e0117517	3
121	Pyrosequencing Unveils Cystic Fibrosis Lung Microbiome Differences Associated with a Severe Lung Function Decline. 2016 , 11, e0156807	19
120	Impact of Long-Term Tiotropium Bromide Therapy on Annual Lung Function Decline in Adult Patients with Cystic Fibrosis. 2016 , 11, e0158193	2
119	The Coupling of Peripheral Blood Pressure and Ventilatory Responses during Exercise in Young Adults with Cystic Fibrosis. 2016 , 11, e0168490	4
118	The intestinal virome in children with cystic fibrosis differs from healthy controls. 2020 , 15, e0233557	7
117	Repeatability and Diagnostic Value of Nasal Potential Difference in a Genetically Admixed Population. 2016 , 8, 15-24	1
116	Bilateral sweat tests with two different methods as a part of cystic fibrosis newborn screening (CF NBS) protocol and additional quality control. 2010 , 48, 358-65	15
115	One-year evaluation of a neonatal screening program for cystic fibrosis in Switzerland. 2013 , 110, 356-63	14
114	Cystic fibrosis and CRMS screening: what the primary care pediatrician should know. 2010 , 39, 759-68	1
113	Chronic cough in children. 2014 , 43, e176-83	3
112	Nanoduct sweat conductivity measurements in 2664 patients: relationship to age, arterial blood gas, serum electrolyte profiles and clinical diagnosis. 2013 , 5, 34-41	7
111	Novel therapeutic approaches for the management of cystic fibrosis. 2020 , 15, 690	4
110	The Saudi Thoracic Society guidelines for diagnosis and management of noncystic fibrosis bronchiectasis. 2017 , 12, 135-161	22
109	Cystic fibrosis revisited. 2019 , 65, 193-196	6
108	Vitamin D Deficiency and Radiological Findings in Adult Non-Cystic Fibrosis Bronchiectasis. 2020 , 21, 87-92	2

107	Association Between Outcomes and Demographic Factors in an Azeri Turkish Population With Cystic Fibrosis: A Cross-Sectional Study in Iran From 2001 Through 2014. 2016 , 18, e29615	6
106	Sleep-disordered breathing in cystic fibrosis pediatric subjects. 2019 , 12, 165-170	6
105	Assessment of Correlation between Sweat Chloride Levels and Clinical Features of Cystic Fibrosis Patients. 2016 , 10, BC01-BC06	5
104	Probabilistic Boolean Modeling of Pre-clinical Tumor Models for Biomarker Identification in Cancer Drug Development. 2021 , 1, e269	0
103	Increasing life expectancy in cystic fibrosis: Advances and challenges. 2021 ,	4
102	Electrochemical detection of chloride ions using Ag-based electrodes obtained from compact disc. 2022 , 1190, 339215	0
101	Genetic Testing and Gene Therapy. 2010 , 258-283	
100	Anesthesia in Pediatric Otolaryngology. 2010 , 2587-2601	
99	Cystic fibrosis newborn screening enables diagnosis of elder siblings of recalled infants--additional benefit. 2010 , 48, 163-5	2
98	Prenatal Diagnosis of Cystic Fibrosis. 577-599	
97	Pediatric Cholestatic Liver Disease with Genetic Etiology. 2011 , 752-766.e3	
96	SELECTED REFERENCES. 2011 , 311-315	
95	Introduction to Section I: the relevance of CF diagnostic tools for measuring restoration of CFTR function after therapeutic interventions in human clinical trials. 2011 , 741, 3-11	
94	Adults with Cystic Fibrosis. 96-114	
93	Cystic Fibrosis. 2012 , 2209-2214	
92	Cystic Fibrosis. 2012 , 545-557	
91	Netter Collection, Medizinischer Atlas, Atmungssystem - Pages 313-319. 2012 , 313-319	
90	Pulmonology. 2012 , 584-605	

89 Clinical Chemistry in Paediatrics.

88 CFTR-Funktionsdiagnostik. **2013**, 307-312

87 Hereditary Exocrine Disorders. **2013**, 59-65

o

86 Genetic and Pediatric Diseases. **2013**, 215-268

85 Zystische Fibrose. **2013**, 587-631

84 Cystic Fibrosis: Carrier Testing, Newborn Screening, and Diagnostic Testing. **2014**, 191-208

83 Cystic Fibrosis. 221-246

82 Miscellaneous Airway Diseases. **2014**, 110-122

81 Cystic Fibrosis. **2016**, 1-16

80 Cystic Fibrosis. **2016**, 189-196

79 Cystic Fibrosis. **2016**, 117-129

78 Utilization Management of Genetic Testing. **2017**, 219-233

77 Ocular Manifestations of Pediatric Pulmonary Diseases. **2017**, 601-615

76 Meconium Ileus. **2017**, 1-19

75 An Introduction to Clinical Aspects of Cystic Fibrosis. **2017**, 3-20

74 Pulmonary Complications of Liver Disease. **2018**, 293-305

73 Nutritional Status, Muscle Strength and Functional Capacity in Children and Adolescents with Cystic Fibrosis. **2018**, 3,

72 Newborn Screening for Cystic Fibrosis in Delaware. **2018**, 4, 44-51

- 71 Microbiology Characteristics Among Cystic Fibrosis Patients in Western Romania. **2018**, 1, 76-82
- 70 Kistik fibrozis yenidođın taramasõsonrasõđlendirilen bebeklerin deđlendirilmesi: dđt yđk tek merkez deneyimi. 1-7
- 69 c.753_754delAG, a novel mutation found in a Chinese patient with cystic fibrosis: A case report and review of the literature. **2019**, 7, 2110-2119 0
- 68 Clinical Assessment of Mucociliary Disorders. **2020**, 103-108 0
- 67 FACTORS ASSOCIATED TO QUALITY OF LIFE IN CHILDREN AND ADOLESCENTS WITH CYSTIC FIBROSIS. **2020**, 38, e2018397 1
- 66 Bacterial Infections and the Respiratory Microbiome. **2020**, 73-92 1
- 65 CFTR modulation with elxacaftor-tezacaftor-ivacaftor in people with cystic fibrosis assessed by the Òadrenergic sweat rate assay. **2021**, 0
- 64 Cystic Fibrosis: Clinical and Diagnosis Approach. **2020**, 439-451
- 63 Meconium Ileus. **2020**, 973-992 1
- 62 Encyclopedia of Behavioral Medicine. **2020**, 588-589
- 61 Cystic fibrosis. **2020**, 4151-4165
- 60 ERKRANKUNGEN DER ATMUNGSORGANE. **2020**, C-1-C22-4
- 59 Clinical, genetic and microbiological characterization of pediatric patients with Cystic Fibrosis in a Public Hospital in Ecuador.
- 58 Clinical, genetic and microbiological characterization of pediatric patients with Cystic Fibrosis in a Public Hospital in Ecuador.
- 57 The Epidemiology and Pathogenesis and Treatment of Pseudomonas aeruginosa Infections: An Update. **2021**, 81, 2117-2131 13
- 56 Drei Jahre Mukoviszidose-Neugeborenencreening Œwie viele und welche Kinder verpassen wir? Mßsen wir noch nach CF suchen?. **2020**, 20, 313-316
- 55 Atypical cystic fibrosis: identification in the primary care setting. **2012**, 58, 1341-5, e699-704 13
- 54 Burkholderia cepacia complex in Indian cystic fibrosis patients. **2012**, 136, 882-3 2

53	Genetics of pancreatitis with a focus on the pancreatic ducts. 2012 , 58, 299-308	6
52	Cystic fibrosis prevalence among a group of high-risk children in the main referral children hospital in Iran. 2017 , 6, 54	3
51	Latest in cystic fibrosis. 2012 , 109, 127-32	
50	A Six-month-old Infant with Respiratory Distress and Cyanosis. 2021 , In Press,	
49	Cystic Fibrosis. 2009 , 30, 302-310	0
48	Vitamins A, D, E status as related to supplementation and lung disease markers in young children with cystic fibrosis.. 2022 ,	1
47	Five cases of missed cystic fibrosis heterozygous mutations identified after a positive newborn screen on a sibling.. 2022 , 36, 101572	
46	Cystic Fibrosis in Children: A Pediatric Anesthesiologist's Perspective.. 2021 ,	1
45	What Is Most Suitable for Children With Cystic Fibrosis-The Relationship Between Spirometry, Oscillometry, and Multiple Breath Nitrogen Washout.. 2021 , 9, 692949	1
44	Review article: epidemiology, pathogenesis and management of liver disease in adults with cystic fibrosis.. 2022 ,	0
43	Cystic Fibrosis. 2014 , 35, 194-205	5
42	AZD5634, an inhaled ENaC inhibitor, in healthy subjects and patients with cystic fibrosis.. 2022 ,	0
41	Chronic cough in cystic fibrosis: the effect of modulator therapy on objective 24-h cough monitoring.. 2022 , 8,	
40	Reactive and Responsive Polymers for Sensing Applications in Bodily Fluids. 1-32	
39	CFTR-mediated monocyte/macrophage dysfunction revealed by cystic fibrosis proband-parent comparisons.. 2022 , 7,	0
38	Things come in threes: A new complex allele and a novel deletion within the CFTR gene complicate an accurate diagnosis of cystic fibrosis.. 2022 , e1926	
37	3D Printed Skin-Wash Sampler for Sweat Sampling in Cystic Fibrosis Diagnosis Using Capillary Electrophoretic Ion Ratio Analysis. 2021 , 8, 234	0
36	The effects of the addition of a new airway clearance device to chest physiotherapy in children with cystic fibrosis pulmonary exacerbations. 2021 , 24, 16-24	0

35	Telemedicine of patients with cystic fibrosis during the COVID-19 pandemic.. 2022 , 40, e2021118	0
34	The effect of TGF- β polymorphisms on pulmonary disease progression in patients with cystic fibrosis.. 2022 , 22, 183	0
33	CFTR protein quantification as a cystic fibrosis diagnostic biomarker in dried blood spots using multiple reaction monitoring tandem mass spectrometry.. 2022 , 216, 114801	0
32	Anesthesia in Pediatric Otolaryngology. 2015 , 21-38.e6	3
31	The effect of antibiotic changes during treatment of cystic fibrosis pulmonary exacerbations. 2022 ,	0
30	Modern Approaches in Management of Children with Cystic fibrosis. 2022 , 19, 153-195	1
29	Integrated diagnostics.	
28	Effects of GLP-1 and GIP on Islet Function in Glucose Intolerant, Pancreatic Insufficient Cystic Fibrosis. <i>Diabetes</i> ,	0.9
27	Case report of a Hispanic female with cystic fibrosis and short stature. 2022 , 39, 101726	
26	Sweat Proteomics in Cystic Fibrosis: Discovering Companion Biomarkers for Precision Medicine and Therapeutic Development. 2022 , 11, 2358	
25	Wearable microfluidic patch with integrated capillary valves and pumps for sweat management and multiple biomarker analysis. 2022 , 16, 044104	2
24	Simple, Skin-Attachable, and Multifunctional Colorimetric Sweat Sensor. 2022 , 7, 2198-2208	5
23	The Exeter Activity Unlimited statement on physical activity and exercise for cystic fibrosis: methodology and results of an international, multidisciplinary, evidence-driven expert consensus. 2022 , 19, 147997312211216	1
22	Galvanic Cell-Based Self-powered Devices. 2022 , 51-80	0
21	Quantification of chloride in sweat by using ion chromatography instead of chloridometer. 2022 , 4,	0
20	Parent's Report on Oral Health-Related Quality of Life of Children with Cystic Fibrosis.	0
19	Update Mukoviszidose. 2022 , 62, 981-994	0
18	Missed Cystic Fibrosis Newborn Screening Cases due to Immunoreactive Trypsinogen Levels below Program Cutoffs: A National Survey of Risk Factors. 2022 , 8, 58	1

- 17 Green and Integrated Wearable Electrochemical Sensor for Chloride Detection in Sweat. **2022**, 22, 8223 ○
- 16 Corneal Refractive Surgery Considerations in Patients with Cystic Fibrosis and Cystic Fibrosis Transmembrane Conductance Regulator-Related Disorders. Volume 15, 647-656 ○
- 15 Unified Airway Disease. **2023**, 56, 11-22 ○
- 14 The association of fecal calprotectin and respiratory exacerbation in cystic fibrosis patients. **2022**, 22, ○
- 13 German newborn screening for Cystic fibrosis: Parental perspectives and suggestions for improvements. ○
- 12 Potential Diagnostic and Monitoring Biomarkers of Obstructive Sleep Apnea Umbrella Review of Meta-Analyses. **2023**, 12, 60 1
- 11 Vending-Machine-Style Skin Excretion Sensing. ○
- 10 International experience in the primary prevention of cystic fibrosis (part two). **2023**, 160-170 ○
- 9 Efficacy of the Simeox[®] Airway Clearance Technology in the Homecare Treatment of Children with Clinically Stable Cystic Fibrosis: A Randomized Controlled Trial. **2023**, 10, 204 ○
- 8 International experience in the primary prevention of cystic fibrosis (part one). **2023**, 150-159 ○
- 7 Manual therapies in cystic fibrosis care: a scoping review. **2023**, 31, ○
- 6 Potentiometric Chloride Ion Biosensor for Cystic Fibrosis Diagnosis and Management: Modeling and Design. **2023**, 23, 2491 ○
- 5 Modelling and Design of an ISFET-Based NaCl Sensor for Cystic Fibrosis Diagnosis and Management. **2023**, 117-121 ○
- 4 Sweat conductivity for diagnosing cystic fibrosis after positive newborn screening: prospective, diagnostic test accuracy study. archdischild-2022-324723 ○
- 3 Economic burden of cystic fibrosis care in British Columbia. **2023**, 7, 60-69 ○
- 2 Skin-Interfaced Wearable Sweat Sensors for Precision Medicine. ○
- 1 *Stenotrophomonas maltophilia* natural history and evolution in the airways of adults with cystic fibrosis. ○